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1. Introduction 
Three layers of protection serve to maintain the health of mammals living in a non-sterile 
environment (Fig. 1). First, physical barriers in the form of epithelial surfaces prevent 
microorganisms from entering the body. These barriers include the skin as well as the 
respiratory and intestinal mucosa. To further discourage colonization of mucosal surfaces by 
microorganisms, they are covered with anti-microbial agents. In addition, ciliary movement and 
muscular contractions in the form of bowel peristalsis and coughing clear the surfaces of mucus 
and trapped microorganisms. Whenever the physical barriers are breached, and microorganisms 
enter the underlying tissues, components of innate immunity are called into play. This second 
line of defense encompasses mechanisms of great diversity, ranging from molecular 
mechanisms such as the complement system, to cellular mechanisms in the form of phagocytic 
macrophages and natural killer cells. Typically, the effectors of innate immunity are pre-formed 
and expressed throughout the body, and may be recruited to the site of infection in a very short 
period of time. 
The innate immune system constitutes a powerful and rapid defense that is able to 
overcome most invading microorganisms. However, in the event that an infectious agent 
manages to break through the first (innate) barriers, a secondary (adaptive) response is elicited. 
The inflammatory mediators provided by the innate effector systems serve to direct the adaptive 
immune response, which constitutes the third and final level of protection. For the adaptive 
immune system to be activated, the invading microorganism must be phagocytosed and 
processed by a dendritic cell (DC), which, in turn, translocates to draining lymph nodes while 
presenting fragments of the microorganism to circulating lymphocytes. Once a cognate 
lymphocyte is activated, it multiplies to create a clone of lymphocytes that all have the same 
antigen specificity. Eventually, the cells of the resulting lymphocyte clone differentiate into 
effector lymphocytes that attack the invading microorganism; either by the production of 
antibodies (B lymphocytes) or pro-inflammatory mediators (helper T lymphocytes), or by 
killing infected cells (cytotoxic T lymphocytes). 
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Figure 1: Major levels of protection in the human immune system. Three consecutive barriers prevent
pathogens from entering the body. First, the epithelial barriers physically block the entry of microorganisms.
Second, in the event that the epithelial barrier is breached, innate immune cells and other innate mechanisms
constitute the immediate response against invading pathogens. Third, upon ingestion of pathogen by dendritic cells
and presentation of peptide fragments to cognate T cells in draining lymph nodes, the adaptive immune response is
initiated, involving clonal expansion of pathogen-specific lymphocytes and the generation of effector molecules
such as cytokines, perforin/granzymes, and antibodies. The pathogen may be warded off at any of these levels.
Should it succeed in evading these defensive mechanisms, however, severe disease may be the result. 
1.1 Check-points of the normal immune response 
The series of events that was outlined above is what constitutes a normal immune 
response. It is well organized, and the different mechanisms of protection are called upon in an 
orderly manner. Most of the microorganisms that the host encounters are neutralized by these 
mechanisms. In the event that they are not, however, they may cause life-threatening and/or 
chronic infections. Thus, the importance of a functioning immune system can hardly be 
overstated. However, the defensive mechanisms entailed in the immune system have 
themselves, occasionally, been known to cause damage to the organism. Illnesses such as 
rheumatoid arthritis and diabetes type 1 are well-known examples of autoimmunity, resulting 
from targeted adaptive immune responses against components of articular or pancreatic tissues, 
respectively. These illnesses occur in spite of numerous safety mechanisms that have been put 
in place to avoid damage to self, and that will be discussed in the following sections. 
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1.1.1 The concepts of central and peripheral tolerance 
Newly formed lymphocytes are tested early in life for their propensity to recognize 
determinants of self. B lymphocytes, being generated in the bone marrow, and T lymphocytes, 
which develop in the thymus, are both subjected to a selection process designed to rid the body 
of potentially self-reactive immune cells (276). This process is known as central tolerance and 
relies on deletion of cells carrying antigen receptors that recognize self antigens. The induction 
of Treg contributes to central tolerance as well, whereas processes such as anergy and receptor 
editing are believed to be of secondary importance (171). Since not all self antigens are 
expressed at the primary sites of lymphocyte development, mechanisms of peripheral tolerance 
have evolved to induce tolerance as the lymphocytes encounter self antigens in the periphery. 
Some of these mechanisms act directly on the responding T cell (T-cell intrinsic mechanisms 
like ignorance, anergy, phenotypic skewing, and apoptosis),whereas others evoke additional 
cell subsets, including tolerogenic DCs and Treg (T-cell extrinsic) (419). Figure 2 summarizes 
the major instances of central and peripheral tolerance. 
Ignorance of self-antigens may represent the simplest setting of peripheral tolerance, yet 
has proven to be an important checkpoint in the development of, for example, murine diabetes 
(17; 170). In this case, tolerance may result from sequestration of the antigen in sites that are 
not easily accessible to the self-reactive T cell (12), or the antigen may not be present in 
sufficiently high concentrations to trigger a T-cell response (214). Anergy, constituting another 
form of peripheral tolerance, can 
manifest itself either intrinsically or in 
a T-cell-extrinsic manner, and results 
in a state of unresponsiveness to 
antigen. The induction of anergy was 
Figure 2: Regulatory mechanisms that
influence T-cell-mediated immunity.
Mechanisms throughout the body contribute
to maintaining immune homeostasis and
keeping the immune system in check in the
absence of pathogens. The generation of T
cells and T-cell-mediated immune responses
are controlled at multiple levels, from the
mobilization of precursor cells in the bone
marrow via differentiation in the thymus to
effector functions in the periphery. 
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initially demonstrated in vitro following ligation of the T-cell receptor (TCR) in the absence of 
co-stimulation (183), but inhibitory co-receptors have since been discovered that are 
responsible for anergy in vivo, including cytotoxic T-lymphocyte antigen (CTLA)-4 (303; 422) 
and programmed death (PD)-1 (221). Notably, CTLA-4 may also be instrumental in the 
suppressive functions of Treg (433). 
Treg play a prominent role in the maintenance of peripheral tolerance, as was 
demonstrated by the reconstitution of athymic nude mice – that lack T cells – with normal T 
cells (21). If the transplanted T cells were depleted of CD4+CD25+ Treg prior to reconstitution, 
the recipient athymic mice were shown to develop multiple autoimmune diseases. Importantly, 
any sign of autoimmunity was avoided by the concomitant administration of CD4+CD25+ 
Treg. These findings were substantiated by studies in mice that were thymectomized early in 
life. Thymic output of CD4+CD25+ Treg commences only at day 3 after birth – in contrast to 
CD4+CD25- T cells, which can be found circulating immediately after delivery (21). Thus, 
thymectomy at day 3 abrogates thymic generation of Treg and leaves an excess of self-reactive 
peripheral T cells largely unchecked, causing organ-specific autoimmune diseases. Depending 
on the mouse strain, this may affect the stomach, thyroid, ovary, testes, or prostate (204). 
The role of innate immunity in directing peripheral tolerance remains somewhat unclear 
(419), although recent observations in for instance allergic diseases indicate that innate immune 
mechanisms involving cytokine production may be used to reinstate immune balance (230). 
Also, the successful use of adjuvants in vaccines to improve the generation of memory 
lymphocytes upon vaccination implicates modulation of peripheral tolerance by innate 
mechanisms (217). Notably, however, we remain largely ignorant of the operating mechanisms 
underlying the majority of adjuvants currently used in vaccines. 
1.1.2 Molecular check-points in antigen presentation 
Through the actions of tissue-resident antigen-presenting cells (APC), microorganisms 
and other potentially noxious agents are digested and presented in a highly specific manner to 
the cells that are best suited for neutralizing them. Thus, specialized APC like the DC infiltrate 
the peripheral tissues and serve as sentinels for the immune system. They continuously sample 
their surroundings and ingest any microorganisms that they come across. Receptors of the 
innate immune system that are expressed by the DC itself sense ‘danger signals’ in the 
surroundings and instruct the DC to bring its contents to the draining lymph node for 
presentation to circulating lymphocytes. The digested antigen (normally a peptide) is presented 
in the context of antigen-presenting molecules such as the major histocompatibility complex 
(MHC) class II, which is only expressed on the so-called ‘professional’ APC (DC, 
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macrophages, B cells, and basophils). Circulating lymphocytes access the presented antigen 
while passing through the lymph node and will, upon recognition, initiate an immune response 
then and there. In the case of viral infections, or infections with other intracellular pathogens, 
the cells that are infected (including non-hematopoietic tissue cells) will present fragments of 
digested antigen in the context of MHC class I. Peptide–MHC class I complexes are, in turn, 
recognized by antigen-specific CD8+ cytotoxic T cells, which initiate directional secretion of 
cytolytic products towards the infected cell in order to kill it by inducing apoptosis. 
Dendritic cells play a major role in directing immune responses, and are known to be 
capable of inducing tolerance as well as immunity. The signals delivered by the DC to a 
responding T cell determine T-cell activation, clonal expansion, and differentiation (46). 
Depending on the activation status of the DC, three signals may be delivered. The first signal 
results from ligation of the TCR by a peptide–MHC complex. However, if delivered by itself, 
this signal will only result in tolerization of the T cell. On the other hand, if provided along with 
a second, co-stimulatory signal, the T cell may become activated. A third signal determines the 
differentiation fate of the T cell. This is transmitted in the form of soluble inflammatory 
mediators released into the surroundings by the DC and accessory cells of the lymph node. Both 
the second and third signals require prior activation of the DC or accessory cells through 
ligation of surface-expressed pattern recognition receptors (PRRs). The PRRs constitute a 
family of innate immune receptors that recognize structurally unrelated but evolutionarily 
conserved pathogen-associated molecular patterns (PAMPs) and include the membrane-bound 
Toll-like receptors (TLR), the cytosolic nucleotide-binding domain and leucine-rich repeat-
containing (NLR) molecules and retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) 
(189; 295). Triggering of these receptors up-regulates the secretion of inflammatory mediators, 
as well as the expression on DCs of the co-stimulatory molecules that provide the second signal 
to cognate T lymphocytes. Thus, the PRRs are important regulators of antigen presentation, and 
constitute a significant means by which DCs are able to distinguish between self and non-self, 
so that only non-self antigens are presented to T cells in the context of potent co-stimuli. (46) 
1.1.3 Leukocyte trafficking – homeostatic and inflammatory motility of immune cells 
The continuous trafficking of immune cells between lymphoid and peripheral tissues 
plays a critical role in maintaining immunity. Even in the absence of inflammatory stimuli, 
some immune cells populate the peripheral tissues, either as resident sentinels or as patrolling 
surveyors. Both innate and adaptive immune cells contribute to this surveillance, which 
facilitates quick responses against potential threats. The polymorphonuclear (PMN) cells 
constitute the first line of cellular defense and are rapidly recruited to sites of infection by 
11 
locally produced inflammatory cues. The APCs, represented in the periphery by macrophages 
and dendritic cells, remain comparatively stationary as they sample their immediate vicinity for 
infectious material. As described above, the APCs will migrate to the draining lymph node in 
the event of pathogen recognition and fulfill its critical role in recruiting the adaptive immune 
system. Moreover, lymph-node resident B cells and basophils continuously engulf and present 
(on MHC II) soluble antigens that are brought to the lymph node through afferent lymphatics, 
thereby providing a second route to the activation of adaptive immunity (366). 
The migration of circulating B- or T lymphocytes from the blood stream into a lymph 
node through high endothelial venules (HEVs) is subject to strict regulation [reviewed in 
(415)]. First, the lymphocyte adheres loosely to the endothelium through the interaction of L-
selectin (CD62L) expressed on its surface with the HEV-expressed glycoprotein GlyCAM-1 
(59; 219). This slows the cell down, and it starts rolling on the endothelial surface under the 
force of the blood stream. The intimate contact with the endothelium and the slow rotation of 
the cell facilitates interaction with chemotactic factors (e.g., chemokines) expressed on the 
endothelium. The expression of the chemokines CC-chemokine ligand (CCL) 21 and CCL19 on 
the HEV vessel wall serves to specifically recruit lymphocytes carrying the CC-chemokine 
receptor (CCR) 7 on their surface. Moreover, rolling B cells may also be recruited by CXC-
chemokine ligand (CXCL) 12, which interacts with the B-cell expressed CXC-chemokine 
receptor (CXCR) 4. Recognition of these chemotactic factors results in upregulation of 
integrins on the surface of the lymphocyte, which mediates firm adhesion through the tethering 
of integrin receptors (intercellular adhesion molecule [ICAM]-1 or -2) presented on HEVs and, 
finally, extravasation of the cell. This three-step process of rolling, firm adhesion, and 
extravasation also applies to the migration of leukocytes from blood vessels into peripheral 
tissues, although the specific chemotactic factors will be different. Thus, the tissue-specific 
expression of chemokines and adhesion molecules 
facilitates targeted trafficking of immune cells. 
Correspondingly, the migratory properties of a 
given leukocyte can be told by the range of homing 
receptors it expresses, which may, in turn, provide 
Figure 3: Chemokine receptor expression profile of CD4+
T-cell subsets. The expression of chemokine receptors
determines the migratory capacities of the CD4+ T-cell
subset, and is influenced by the transcriptional regulation of
the cell. Adapted from Ward et al., 2009 (424). 
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important clues regarding its functional roles. The chemokine receptor expression profiles of 
central CD4+ T-cell subsets are presented in Figure 3. 
1.1.4 Co-stimulation – the fruits of an inflammatory milieu 
For a proper understanding of how the immune system is regulated, one fundamental idea 
that must be deliberated is the concept of co-stimulation. Co-stimulation lies at the very heart of 
immune regulation, being the decisive mechanism that balances tolerance and immunity in any 
given immune response. The importance of co-stimulation was first appreciated in 1970 by 
Bretscher and Cohn (60), who realized that the activation of an antigen-specific lymphocyte 
response required at least two distinct signals from the APC. It has since been determined that 
co-stimulation may be provided in several different ways – two of them being through ligands 
presented on the plasma membrane of APCs, or soluble factors released either by the APC itself 
or by accessory cells – and that the co-stimulatory factors may utilize a variety of intracellular 
signaling pathways to mediate survival or to offer proliferative cues (7; 209; 369). 
The B7:CD28 family of co-stimulatory molecules plays a central role in regulating 
adaptive responses, and members of this family, in particular CD28 itself (see Fig. 4), directly 
control the activation status of T cells upon antigenic stimulation (7). Importantly, there is a 
quantitative relationship between the number of ligated TCR on a T cell and the likelihood of 
activating the cell – i.e., releasing it from the resting state (G0 phase) to enter the cell cycle – 
resulting in proliferation and differentiation, and the initiation of an adaptive immune response. 
If the density of properly presented antigen is very high, it is actually conceivable that the T cell 
may proceed to proliferation and differentiation in the absence of co-stimulation. However, in 
vivo, the concurrent availability of co-stimulatory agents is an absolute prerequisite for 
maintaining a vigilant immune system and preventing disease. Mice lacking CD28 present with 
Figure 4: Effects of CD28 co-stimulation.
The prominent role of CD28 in promoting 
complete T-cell activation results from direct 
effects (left) on gene activation, cell cycle and 
survival, and from inducing the expression of a 
second wave of membrane receptors by 
activated T cells. The indirect effects (right) on 
clonal expansion and T-cell differentiation 
further underscores the importance of CD28 as 
a co-stimulatory factor. AP1, activator protein 
1; NFAT, nuclear factor of activated T cells; 
NF-κB, nuclear factor κB; Th, T helper cell. 
Adapted from Acuto et al., 2003 (7). 
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reduced responses to a variety of immune challenges, as is also the case in mice that are devoid 
of the CD28 ligands CD80 and CD86 (7). Thus, co-stimulation through ligation of CD28 on the 
T cell by APC-expressed CD80 or CD86 is an important requirement for initiating a productive 
immune response. Other important co-stimulatory receptors include CD2 and the β2-integrin 
leukocyte function-associated antigen 1 (LFA-1), yet these cannot rival the stimulatory capacity 
of CD28 (444). Cytokines constitute another set of co-stimulatory molecules known to 
influence T-cell activation. In addition, the presence of inhibitory co-receptors may negatively 
regulate TCR stimulation, causing suppression of T-cell activation if qualitatively 
outnumbering the co-stimulatory receptors. Important co-inhibitory molecules include CTLA-4 
and PD-1, also of the B7:CD28 family (148). 
1.1.5 The importance of lymphoid tissues in directing immunity 
The term “lymphoid tissue” denotes a collection of tissues dedicated to the generation of 
immune cells and induction of immune responses. The primary lymphoid tissues, including the 
bone marrow and the thymus, constitute veritable immune-cell cradles since this is where all 
blood cells originate. The secondary lymphoid tissues, encompassing the spleen and the 
peripheral lymph nodes, are hubs distributed throughout the body in which immune cells meet 
and adaptive immune responses are generated. In the primary lymphoid tissues, pluripotent 
hematopoietic stem cells (HSCs) differentiate and proliferate to replenish the blood cells that 
are lost in immune responses or due to homeostatic turnover. Thus, one fundamental step of 
immune regulation concerns the tightly regulated process of hematopoiesis, which involves the 
generation of new immune cells from HSCs in primary lymphoid tissues. Each subset of 
immune cells requires distinct growth factors, which are provided to the HSCs by the 
specialized microenvironment in niches created by committed accessory cells. These express 
and secrete factors that regulate the HSC homeostasis and regeneration, as well as its 
differentiation into specific hematopoietic lineages (195). 
The secondary lymphoid tissues constitute hubs for the initiation of adaptive immune 
responses, and serve to facilitate the specific interactions required for activation of T- and B 
lymphocytes. This function is reflected in the lymph node architecture (Fig. 5): Naive T cells 
enter the lymph node from venous blood through the specialized HEVs (415). Following 
extravasation, which requires the expression of CD62L, CCR7, and LFA-1, the T cell enters the 
T-cell rich paracortex of the lymph node. Here it encounters antigen in the context of MHC 
class II as presented by either mature DCs that have migrated from the periphery through 
afferent lymph, or resident B cells or basophils that have captured antigen directly from lymph. 
In the event that the CD4+ T cell encounters its cognate antigen, it becomes activated and 
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transiently expresses CXCR5 while down-regulating CCR7 to be able to leave the T-cell area 
and translocate to the B-cell rich primary follicles (339). Here, they interact with and stimulate 
cognate B cells to initiate a humoral immune response. The T cell may also exit the lymph node 
through an HEV and migrate to the area where the immune response originated, to direct 
immunity there. 
Figure 5: Lymph node architecture. The main routes of lymph flow are indicated by white arrows (left).
Enlarged section: Circulating T cells enter the lymph nodes through high endothelial venules (HEVs) and
encounter antigen-presenting cells in T-cell rich areas situated near B-cell zones (green spheres). T cells that meet
cognate antigen and are activated undergo several steps of proliferation and differentiation, before progressing
either to the adjacent B-cell zone, where they facilitate activation of antigen-specific B cells, or to the periphery,
where they promote killing of pathogen and pathogen-infected cells. Adapted from von Andrian et al., 2003 (415).
The central role of lymph nodes in the generation of adaptive immune responses implies a 
role in controlling immunity. Importantly, the trafficking of immune cells through the lymph 
node is restricted to certain subsets of immune cells, and it may also be regulated upon 
inflammation to improve the chances of eliciting a productive immune response. Our 
knowledge concerning these processes remains limited, however, but the recent advent of 
multiphoton microscopy of intact tissues in live animals has greatly improved our 
understanding of the dynamics of antigen presentation (87). 
1.2 The players of adaptive immunity 
Keeping the body free of pathogens and avoiding the development of malignancies is a 
very demanding task, which has to be solved with a certain level of finesse in order to avoid 
exhausting the body’s resources. While facing an enormous number of potential intruders, the 
challenge once lay in finding a way of neutralizing all conceivable threats at a minimum of 
energy expenditure. As previously outlined, the innate immune system serves an important role 
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in fending off most of the attacks. However, as soon as the pathogen has breached the innate 
defenses and established itself inside the body, another level of sophistication is required. While 
the organism continuously runs the risk of being overthrown by foreign and uninvited powers, 
simultaneously preparing for all of these risks by stock-piling immune cells in every flavor has, 
throughout evolution, proven too costly. Instead, the remedy to our needs evolved some 500 
million years ago in the form of rearranging antigen receptors, resulting over the following 
years in an adaptive immune system capable of targeting and expelling any invader. The price 
to pay, however, is that it will only do so after a couple of rounds of cellular expansion and 
differentiation, resulting in a lag-time of about 4-7 days throughout which we depend on the 
innate immune mechanisms for our safety and wellbeing. 
Another key feature of adaptive immunity is the ability to develop immune memory, 
enabling rapid and potent immune responses upon re-exposure to antigens that have been 
encountered previously (113). Following an immune response, most of the clonally expanded 
T- and B lymphocytes are killed in the interest of immune homeostasis. However, some cells 
are fed survival signals and redirected through a series of differentiation steps to become 
memory cells. These cells are maintained for future reference should the same antigen reoccur 
at a later time-point, and constitute what is known as immunological memory. In the event of a 
second response against the same pathogen, these memory cells will respond more quickly and 
with greater vigor than naive T cells. 
1.2.1 The different faces of immunological memory 
As mentioned in Chapter 1.1.3, tissue homing is an important mechanism for directing 
immune responses: Naive T cells are largely migratory cells that circulate the blood stream 
while searching for their cognate antigen, yet they require the ability to enter lymph nodes and 
encounter activated DCs in order to become properly activated. Once activated, they 
differentiate into effector T cells, which express homing receptors that allow them to home to 
lymph-node B-cell zones or the site of infection. Finally, as the infection resolves and most of 
the effector cells undergo apoptosis, two distinct sets of surviving memory T cells are 
distinguishable based on their expression of the lymph-node homing receptors CD62L and 
CCR7; central memory T (TCM) cells (CD62L+CCR7+) and effector memory T (TEM) cells 
(CD62L-CCR7-) (253; 333). Thus, whereas the TCM cells have a tendency for accumulating in 
lymphoid tissues, the TEM cells remain in the periphery as sentinel cells. 
Interestingly, the TEM cells may be targeted specifically to the organ in which they were 
originally primed (435). Thus, TEM cells that were initially activated in gut-associated lymphoid 
tissues (GALT) will acquire a phenotype that allows them to home to the gut mucosa. This can 
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be achieved by the expression of α4β7-integrin and the CC-chemokine receptor CCR9, which 
will interact with the gut-associated mucosal vascular addressin cell adhesion molecule 1 
(MadCAM1) and CCL25, respectively (70; 318). In contrast, skin-homing T cells express 
CCR4 and/or CCR10, which recognize the dermal-associated chemokines CCL17 and CCL27 
(213; 449). It is the local microenvironment that instructs the expression of tissue-specific 
homing receptors on TEM cells, a process that is influenced by the route of infection and the site 
of replication, yet independent of the type of pathogen (69; 156; 184; 265). Moreover, the 
homing phenotype is flexible and can be changed during a secondary pathogen challenge 
depending on the site of activation and replication of the TEM cells (110; 266). 
The memory T-cell pool is maintained over time by homeostatic proliferation driven by 
IL-7 and IL-15 (380). However, whereas the TCM cells are maintained for a life-time, the 
peripheral TEM cells gradually decrease in numbers (162; 169). It appears that the TEM cells are 
eventually replaced by circulating TCM cells, yet the TCM cells are equally capable of mounting 
secondary immune responses once in the peripheral tissues (435). For several months after an 
infection, residual antigen expressed on activated DCs in the draining lymph node may 
contribute to the maintenance of the peripheral memory T-cell pool through the activation of 
TCM cells (451). However, following the depletion of the residual antigen depots, TCM cells 
continue to be exported to the periphery by an unknown, antigen-independent mechanism 
(203). Importantly, in the event of a secondary infection, the maintenance of a peripheral pool 
of memory T cells ensures not only rapid initiation of effector functions locally at the site of 
infection, but also the quick generation of an effective secondary immune response that does 
not require priming of naive T cells (435). 
Memory T cells do not depend on co-stimulation for activation and may be activated in 
the periphery upon antigen recognition (93). Thus, although they still require antigen 
presentation in the context of MHC molecules, they are able to bypass some of the regulatory 
mechanisms that would normally safeguard the fidelity of immune activation. As a 
consequence, they have been suggested to mediate immune pathology upon viral infection (81; 
240) and transplantation (190), as well as causing autoimmunity (403). The question is whether 
immunotherapeutic targeting of memory subsets may relieve clinical immune pathologies. This 
is further debated in the Discussion of this Thesis. 
1.2.2 Polarization of the immune response 
Upon activation by a DC, the CD4+ T cell may differentiate into one of several different 
effector T-cell lineages (Fig. 6). For the time being, the established lineages include the T 
helper type 1 (Th1), Th2, Th17, and follicular T helper (Tfh) lineages plus the induced Treg 
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(iTreg) lineage (459). As the CD4+ T cell is activated, its fate is decided mainly by the 
cytokines present in its environment and, secondly, the strength of the TCR signal it receives 
(57). The prevailing dogma, which was established in the late eighties, describes a dichotomy 
between the Th1 and Th2 lineages (268). It was believed that the CD4+ T cell chose one of 
these two fates upon activation, and that they would inhibit each other reciprocally through the 
secretion of lineage-specific cytokines. It was further believed that the choice of lineage 
represented a stable and irreversible differentiation state, and that the two lineages would 
maintain their cytokine profiles even under conditions that would normally promote the other 
lineage (272). However, the idea of stably differentiated lineages has been challenged with the 
recent discovery of another lineage of T helper cells, the Th17 cells, and the advent of inducible 
Treg cells. Moreover, the very recent identification of a ‘Th22’ lineage, and the suggestion that 
Th2 cells might differentiate into IL-9-secreting ‘Th9’ cells, further strains the current dogma 
(111; 400; 459). 
The different T helper lineages have distinct cytokine profiles, and serve distinct tasks in 
vivo. Th1 cells secrete predominantly interferon (IFN)-γ and direct cellular immune responses 
against viruses and intracellular bacteria. Th2 cells, on the other hand, are mainly involved in 
humoral responses against helminths and extracellular pathogens, and produce a cocktail of 
interleukin (IL)-4, IL-5, and IL-13. The recently identified Th17 cells are believed to control 
responses against extracellular bacteria and fungi – especially at mucosal surfaces – and secrete 
IL-17A and IL-17F, as well as IL-22 (459). The production of cytokines and other effector 
molecules is regulated through the actions of lineage-specific transcription factors; T-box 
expressed in T cells (T-bet) in Th1 cells; GATA-binding protein-3 (GATA-3) in Th2 cells; and 
retinoid orphan receptor-γ-t (RORγt) in the Th17 lineage. The Tfh lineage secretes IL-21 and 
appears to require IL-12 and/or IL-21 plus the transcription factor B-cell lymphoma-6 (Bcl-6) 
for differentiation, and serves to regulate the maturation of B-cell responses in lymphoid tissues 
(117; 246; 285; 414). The iTreg may entail several different putative lineages, including T 
regulatory 1 (Tr1) and Th3. Whether or not these constitute distinct lineages remains a matter of 
debate – as goes for the fact that several of the characterized iTreg lack the expression of 
forkhead box protein-3 (FOXP3), even though this transcription factor has been hailed a 
specific factor defining the Treg population (349). 
Extensive inter-lineage cross-regulation contributes to the consolidation and stability of 
the T helper lineages. For example, the Th2-expressed cytokine IL-4 represses commitment to 
the Th1 lineage by inhibiting the expression of IL-12Rβ, thereby antagonizing the important 
cues of IL-12 in Th1 lineage differentiation (383). Correspondingly, the induction of T-bet by 
IFN-γ inhibits Th2 differentiation by upregulation of the transcription factor Runx3, which 
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interacts with the Ifng promoter and the Il4 silencer, respectively (107; 274). Furthermore, IFN-
γ and IL-4 both inhibit the induction of IL-17 (161; 463). It is not clear, however, whether cells 
of the Th17 lineage cross-regulate the differentiation of Th1 or Th2 cells (459). 
1.2.3 A new paradigm for polarized immunity 
The T helper lineages, which were originally thought to represent stable commitments 
governed by epigenetic changes and controlled by specific “master regulator” transcription 
factors (18; 45; 272), have recently been challenged by the discovery of Th17 and iTreg 
lineages that demonstrate unprecedented instability (223; 229; 294; 438). For example, Th17 
Figure 6: The cytokine milieu determines CD4+ T-cell differentiation and conversion. As the naive T cell
encounters cognate antigen presented by antigen-presenting cells it undergoes activation, proliferation, and
differentiation. Its fate, however, depends on the presence or absence of certain cytokines in the surroundings. In
the presence of IFN-γ and IL-12, for instance, the T cell is likely to differentiate into and produce cells of the Th1
lineage. Correspondingly, IL-4 promotes differentiation of Th2 cells, whereas IL-6 and TGF-β favors the Th17
lineage. Furthermore, the recently identified Th22 lineage is advanced by a combination of IL-6 and TNF, while
the Tfh cells result from the combined effects of IL-12 and IL-21. Moreover, the induction of iTreg cells benefits
from a combination of TGF-β, RA, and IL-2. Finally, it has been suggested that cells of the Th2 lineage may be
differentiated into IL-9-producing Th9 cells, though this finding remains to be substantiated. The different CD4+
T-cell lineages are driven by lineage-specific transcription factors; T-bet for Th1, GATA-3 for Th2, RORC for
Th17, RORC and AHR for Th22, and FOXP3 for iTreg. The various lineages were previously thought of as
terminally differentiated phenotypes, yet recent findings indicate a high degree of plasticity and inter-convertibility
between the lineages, as indicated by the arrows. Adapted from Zhou et al., 2009 (459). 
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cells have been observed to convert into Th1 or Th2 cells in the presence of IL-12 or IL-4, 
respectively (223; 229), whereas iTreg have been perceived to express IL-17 following 
prolonged exposure to a pro-inflammatory environment (294; 438). In addition, recent 
observations indicate heterogeneity in the Th17 lineage, for instance by the identification of IL-
17+IL-22- cells in the presence of high levels of transforming growth factor-β (TGF-β) (458). 
Furthermore, Th17 cells differentiated in vitro in the absence of IL-23 but in the presence of 
TGF-β and IL-6 were shown to have reduced pathogenic potential in the murine experimental 
autoimmune encephalomyelitis (EAE) model, allegedly as a result of upregulation of the 
regulatory cytokine IL-10 in the Th17 cells and ensuing bystander suppression (257). 
The observed instability of Th17 cells may have important consequences for in vivo 
immune responses and immune homeostasis. For instance, IL-10-secreting Th17 cells may 
confer protection to mucosal tissues even in the presence of the inflammatory cytokines IL-6 
and TGF-β. On the other hand, upregulation of IL-23 may increase the pathogenicity of the 
Th17 cells (257). The apparent reliance of the Th17 lineage on stable expression of pro-
inflammatory cytokines in their surroundings points to the importance of commensal bacteria in 
maintaining a Th17-polarizing environment. In fact, several studies have demonstrated 
detrimental effects of antibiotic treatment on the differentiation of Th17 cells, followed by 
complications such as secondary infections and diarrhea (22; 112; 155; 179). Moreover, the 
observed instability of Treg lineages may have implications for the clinical utilization of Treg 
in preventing inflammatory or autoimmune diseases, since Treg cells that convert into IL-17-
secreting cells may exacerbate the inflammatory condition that they were intended to treat. 
In summary, emerging evidence now indicate that the T cell fate is dynamic, rather than 
irreversible, and that the currently held view that T cells are segregated into lineages 
insufficiently describes the multitude of possible T-cell fates (459). Rather, a system based on 
lineages may be limited to crudely describing the properties of T cells based on their functional 
repertoire (i.e., the cytokines they secrete). Importantly, the newfound understanding of helper 
T cells as a malleable entity marks the beginning of a new paradigm wherein local cues 
provided to the T cell by its environment may override the instructions that were initially given 
to it. Moreover, this new paradigm comes with the ability of modifying and fine-tuning immune 
responses by the use of external factors, and may revolutionize the way we treat immune-
mediated diseases. For instance, provided exhaustive knowledge of the factors balancing an 
immune response, we may be able to design and administer a cocktail of cytokines invoking not 
only generalized immune suppression or immune stimulation but a nuanced response that 
ensures immunity yet prevents immune pathologies. 
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1.3 Immune-cell signaling and activation 
The T cells generated in the thymus represent a pool of naive T cells that are, collectively, 
designed to recognize any structure presented to them in the context of an MHC molecule. The 
challenge, then, lies in finding and activating the best suited T cell for any given pathogen – and 
avoiding the activation of T cells that recognize structures related to self. Peptide–MHC 
complexes binding the TCR with virtually any affinity will be presented to it, and it is the key 
task of the TCR to distinguish between peptides derived from self and non-self, respectively, 
based on their affinity and additional cues presented to it through co-stimulatory molecules. The 
TCR-CD3 complex consists of a clonotypic αβ TCR dimer that is coupled to six subunits 
(CD3γε, CD3δε, and CD3ζζ pairs), which are responsible for transducing the signal by 
recruiting cytoplasmic or membrane-bound signaling proteins to a larger multiprotein scaffold 
capable of diversifying the signal and inducing the expression of multiple target genes (5). 
Moreover, several regulatory mechanisms serve to influence the TCR signal, intersecting on the 
level of both proximal and distal signaling molecules to fine-tune the signal and control the 
outcome. 
1.3.1 Proximal TCR signaling 
The immediate events following ligation of the TCR by cognate antigen (illustrated in 
Fig. 7) determine whether or not the T cell will be activated, or if it will become anergic. This 
depends not only on TCR-ligation but also on the presence of co-stimuli (5). The affinity with 
which the antigen binds the TCR influences the strength of the ensuing TCR signal and 
influences the fate of the cell. The first event following engagement of the αβTCR is the 
recruitment of Lck, which phosphorylates immunoreceptor tyrosine-based activation motifs 
(ITAMs) in the cytoplasmic tails of the CD3 subunits. Notably, the co-receptors CD4 and CD8 
are associated with Lck and could possibly serve to co-localize Lck with the CD3  -chains – 
although this may also be achieved by targeting to glycosphingolipid-enriched membrane 
microdomains (GEMs), also known as lipid rafts (109). When Lck has phosphorylated both 
tyrosines of one ITAM, ζ-chain-associated protein kinase of 70 kDa (ZAP70) is recruited 
through its tandem SH2 domains (405) and activated by Lck-mediated phosphorylation (6). 
Activated ZAP70, in turn, phosphorylates the GEM-associated linker for activation of T cells 
(LAT) on several of its tyrosine residues, inducing the recruitment of various downstream 
effector proteins. 
The SH2-domain-containing leukocyte protein of 76 kDa (SLP76) is a crucial component 
of the resulting signaling scaffold, binding tightly and cooperatively with multiple kinases and 
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adaptor proteins. SLP76 binds LAT indirectly through growth-factor-receptor-bound protein 2 
(GRB2)-related adaptor protein (Gads), and tethers phospholipase Cγ1 (PLCγ1) in the other 
end, acting as a bridge between the two. It also serves to bind other enzymes such as the IL-2-
inducible T-cell kinase (ITK), Vav, and son of sevenless homologue (SOS; not shown in Fig. 7) 
and concentrate them with their substrates so as to facilitate high-specificity interactions of 
medium-range affinities. The ensuing diversified signaling cascades elicit responses affecting 
as distinct cellular tasks as cell adhesion, cytoskeleton rearrangement, and gene expression. (5) 
Proximal TCR signaling is regulated by a number of refined mechanisms designed to 
distinguish between self and non-self. For instance, the duration of a TCR–peptide–MHC 
interaction will vary depending on the nature of the peptide, and will result in different signals 
depending on its ‘dwell time’. The longer dwell times of foreign peptides will ensure full 
calcium signaling, which may in turn induce the formation of an immunological synapse (178). 
A longer dwell time also favors a stronger signal by inducing increased phosphorylation of the 
cytoplasmic tails of the CD3 subunits (192). In addition, the availability of active (Y394-
phosphorylated) Lck influences the signal strength (159). The activation of Lck is, in turn, 
negatively regulated by a signaling module consisting of CD45, Csk, Csk-binding protein 
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Figure 7: Modular functions of the TCR signalosome. The lipid raft-associated protein PAG regulates T-cell
receptor (TCR) signaling by recruiting the Lck-inhibitory Src‑family protein tyrosine kinase (PTK) C-terminal Src
kinase (Csk), which phosphorylates Lck at the C-terminal tyrosine residue (Tyr505), thereby maintaining Lck in an
inactiv0e state. The activation of Csk is thought to be mediated by anchored PKA (see Chapter 1.5.3), whereas
dissociation of Csk upon dephosphorylation of PAG may be responsible for relieving the inhibition of Lck after
TCR stimulation. Lck is further activated by the combined efforts of the protein tyrosine phosphatase (PTP) CD45
and the adaptor TSAD, as shown in the insert. This results in equilibrium between the active, primed, and inactive
forms of Lck, the position of which determines the excitability of TCR signaling. Upon ligation of the TCR, active
Lck may phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 ζ-chain, as well as
tyrosine residues of the TCR-proximal kinase ZAP70, which is recruited to the phosphorylated ITAMs and
assembles the signal diversification and regulation module through phosphorylation of the scaffold proteins LAT
and SLP76. This module encompasses regulators of Ca2+ signaling, actin polymerization, and integrin activation,
and controls cellular processes like cell adhesion, cytoskeletal rearrangements, and gene expression, which are
required for activation, proliferation, and differentiation of the T cell. ADAP, adhesion‑ and
degranulationpromoting adaptor protein; AP1, activator protein 1; ARP, actin‑related protein homologue; CDC42,
cell‑division cycle 42; DAG, diacylglycerol; Gads, growth‑factor‑receptorbound‑protein‑2‑related adaptor
protein; InsP3, inositol‑1,4,5‑trisphosphate; ITK, interleukin‑2‑inducible T‑cell kinase; MAPK,
mitogen‑activated protein kinase; NCK, non‑catalytic region of tyrosine kinase; NFAT, nuclear factor of activated
T cells; NF‑κB, nuclear factor‑κB; PAG, phosphoprotein associated with glycolipid‑enriched membrane domains;
PAK, p21‑activated kinase; PKC, protein kinase C; PLCγ1, phospholipase Cγ1; SHP1, SRC homology 2
(SH2)‑domain‑containing protein tyrosine phosphatase 1; SKAP55, SRC‑kinase‑associated phosphoprotein of 55
kDa; SLP76, SH2-domain‑containing leukocyte protein of 76 kDa; TSAD, T‑cell‑specific adaptor protein;
WASP, Wiskott–Aldrich syndrome protein; ZAP70,  ‑chain‑associated protein kinase of 70 kDa. Adapted from
Acuto et al., 2008 (5). 
(CBP)/phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), T-cell 
specific adaptor protein (TSAD), lymphoid tyrosine phosphatase (LYP), SH2-containing 
protein tyrosine phosphatase (SHP)-1, and extracellular signal-regulated kinase (ERK) (5). 
SHP-1 is rapidly recruited to the cell membrane upon high doses of antagonist peptide–
MHC complexes in naive T cells to dephosphorylate and inactivate Lck, thereby increasing the 
threshold for T-cell activation and filtering out noise generated by the presence of self-peptide–
MHC complexes (197; 233; 370). It is not known precisely how SHP-1 is recruited to the TCR, 
but it appears to become activated by Lck upon antagonist ligation of the TCRαβ and upon 
binding to immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in the cytoplasmic tails of 
the TCR complex, eventually reducing Lck activity by an, as yet, unknown mechanism (233; 
298; 370). The micro-RNA mir181a has also been shown to regulate Lck activity, as it down-
regulates the phosphatases LYP, SHP-2, dual-specificity protein phosphatase (DUSP)-5, and 
DUSP-6 and strongly augments TCR sensitivity (233). These regulatory mechanisms are 
23 
expressed at different levels throughout thymic development, suggesting a stage-specific fine-
tuning of TCR sensitivity (100). Another immediate negative feedback mechanism involves a 
complex formed around the adaptor proteins known as downstream of kinase (DOK)-1 and 
DOK-2, which interact with LAT and control membrane recruitment of pleckstrin homology 
(PH)-domain-containing signaling effectors, such as Akt, through SH2-domain-containing 
inositol-5-phosphate 1 (SHIP1)-mediated hydrolysis of the second messenger 
phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3) (108; 164; 445). This mechanism is 
thought to contribute to reducing signal noise and improving signal specificity. Furthermore, 
Dok1-/-Dok2-/- mice suffer from loss of negative control of cytokine signaling and augmented 
activities of ZAP70, LAT, and ERK, ultimately causing alterations in myeloid-cell homeostasis 
and spontaneous lupus-like autoimmunity (108; 281; 445; 446). 
In addition to the previously mentioned proximal mechanisms of regulation, other 
mechanisms act on the TCR signalosome at later time points following the event of TCR 
triggering. These include the HPK1–SLP76–14-3-3 pathway and the suppressor of TCR 
signaling (STS) proteins. Phosphorylation of the hematopoietic progenitor kinase (HPK)-1 is 
induced by Lck or ZAP70 upon TCR triggering, causing it to bind SLP76 or other scaffold 
proteins (49; 238; 338), upon which HPK1 phosphorylates serine 376 of SLP76 and induces the 
interaction of SLP76 with 14-3-3 proteins, with the potential to regulate a series of cellular 
processes (105; 247; 354). The phosphorylation of SLP76 peaks 10-15 minutes after TCR 
stimulation and is maintained for up to 1 hour, suggesting a delayed onset of the HPK1–
SLP76–14-3-3 negative feedback loop (105). Ubiquitylation regulates the degradation of 
proteins in general (see Chapter 1.3.5), and specifically influences the balance between immune 
activation and tolerance through the actions of ubiquitin ligases of the Casitas B-lineage 
lymphoma (CBL) family. The ubiquitin ligases CBL-B, gene related to anergy in lymphocytes 
(GRAIL), and Itch serve to down-regulate components of the TCR signalosome through 
activation-dependent degradation, thereby enforcing T-cell anergy (166; 242). Ubiquitylation is 
positively or negatively regulated by protein tyrosine phosphorylation, and CBL-family E3 
ubiquitin ligases are recruited to the TCR signalosome upon activation, resulting in down-
modulation of T-cell signaling by a mechanism dependent on STS-1 and STS-2 (118; 208; 
436). These suppressor proteins show some redundancy, but their importance is demonstrated 
in Sts1-/-Sts2-/- mice, which have increased activation of ZAP70, SLP76, LAT, and ERK and 
are more susceptible to induced autoimmunity in EAE models (74; 260). 
The numerous regulatory mechanisms mentioned above serve to indicate the level of 
stringency underlying TCR signaling. In the present Thesis, we have discussed the possible role 
of the cAMP–PKA–Csk inhibitory pathway in regulating this crucial step of immune activation 
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(see Chapter 1.5.3), but it should be stressed that this is only one contributing mechanism out of 
several. It should also be noted that the various mechanisms may operate at distinct stages of 
development, or under specific conditions, and that they may be partly overlapping or strictly 
non-redundant. 
1.3.2 Cytokine signaling 
Cytokine signaling is known to play an important role in immune regulation and 
inflammation, and mutations in important components of the cytokine signaling machinery 
have been related to a variety of immune pathologies (290). Cytokine receptors are expressed 
on the surface of all nucleated cells within the human body and serve a variety of functions as 
parts of the intercellular lines of communication. The conserved family of type I and II cytokine 
receptors comprise around 40 receptors, including the interleukin receptors as well as hormone 
and growth-factor receptors (53). Ligation of a receptor by its cognate cytokine results in 
activation of intracellular signaling cascades that culminate in the generation of specific 
transcription factors and transcription of target genes. Thus, cytokine signaling constitutes a 
way of regulating gene expression in the responding cell (290). Depending on the cytokine and 
the nature of its receptor, genes may be turned on or off, invoking changes that may affect both 
the phenotype and the functional properties of the target cell. In Paper 1, a population of T cells 
secreting the cytokine IL-10 was observed to suppress the proliferation of effector T cells. 
Whether or not IL-10 was part of their suppressive capacity could not be ascertained in this 
study, yet IL-10 has been established as a cytokine with strong immunomodulatory properties 
and it is not unlikely that it did play a role in the observed suppression. Indeed, IL-10 has been 
found responsible for the inhibition of T-cell effector functions mediated by the Tr1-type 
regulatory T cells (see Section 1.4). 
The binding of a cytokine to its receptor causes receptor dimerization and the subsequent 
activation of Janus kinase (JAK) family tyrosine kinases, which are constitutively associated 
with the receptor. The activated JAKs phosphorylate specific tyrosine residues in the 
cytoplasmic tail of the receptor, which in turn recruit SH2-binding latent cytoplasmic 
transcription factors of the signal transducer and activator of transcription (STAT) family. The 
STATs dimerize following activation by JAKs, then translocate to the nucleus where they bind 
DNA and activate gene transcription (99; 225). 
Several instances of cytokine signaling are outlined in Figure 8. Thymic development of 
T cells requires activation of STAT5 through ligation of the IL-7 receptor and signaling through 
JAK3, and mice negative for key components of the IL-7–JAK3–STAT5 pathway fail to 
develop T cells (289; 441). Moreover, the different fates of activated helper T cells depend on 
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the cytokine milieu at the time of activation. Hence, IL-12 directs differentiation into the Th1 
lineage whereas IL-4 drives Th2-cell differentiation. Studies in knockout mice have 
demonstrated these responses to be dependent on STAT4 and STAT6, respectively (286). 
Furthermore, the main cytokine products of these two lineages – IFN-γ for Th1 cells and IL-4 
for Th2 cells – promote the commitment of the differentiated cells to their lineage and inhibit 
differentiation into the opposing lineage. The generation of Treg is also subject to cytokine 
regulation, be it the development of nTreg in the thymus or induction of iTreg in the periphery. 
Both of these regulatory FOXP3-expressing subsets depend on cytokines that bind the γ-chain 
(γc), and deficiency of γc or JAK3 therefore results in a failure to produce FOXP3-positive 
Treg (254). Correspondingly, a deficiency in STAT5, which is down-stream of JAK3 and 
directly regulates the transcription of the FOXP3 gene, also results in loss of Treg and inability 
to induce Treg in vitro (65; 442). The Th17 lineage, on the other hand, depends critically on 
activation of STAT3, which is achieved upon binding of IL-6, IL-21, or IL-23. Activated 
STAT3 directly regulates the expression of RORγt and RORα, as well as IL-17 and IL-21 (86; 
427; 439). Interestingly, IL-2 acting through STAT5 counteracts Th17-cell differentiation 
(220), and the balance between Treg and Th17-cell differentiation thus appears, in part, to be 
regulated by STAT5 and STAT3, respectively (290). 
Cytokines are potent immune regulators and their actions are therefore tightly regulated (353). 
Hence, the activation of STATs leads to induction of a family of cytokine-induced inhibitors 
termed suppressors of cytokine signaling (SOCS), which bind intracellular domains of specific 
cytokine receptors and block the generation of STAT signals from the receptor (11; 447). 
Importantly, SOCS genes are among the targets of activated STATs, providing a negative 
feedback mechanism for regulating the output of cytokine signaling. Among the eight SOCS 
proteins, SOCS1 and SOCS3 mediate most of the immunoregulatory effects in humans, 
universally affecting the activation, differentiation, and homeostasis of immune cells (11; 447). 
The SOCS proteins have been suggested to participate in multiprotein complexes that direct 
substrate proteins to the proteasome for degradation, but their mechanism of action remains to 
be resolved (196; 290; 447; 453). 
According to three recent reports, cytokines and cytokine signaling play a crucial role, as 
well, in the directional actions of Treg (79; 202; 456). In keeping with these reports, the local 
cytokine environment not only mediates polarization of the immune response but also 
determines the effector subsets targeted by Treg for suppression. For instance, the activation of 
STAT3 by ligation of the Th17-promoting cytokines IL-6 and TGF-β may endow Treg with the 
ability to suppress Th17 responses. As mentioned in Section 1.4.3, similar mechanisms have 
been found to regulate Th1 and Th2 responses. Anomalies in the cytokine signaling network 
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Figure 8: Cytokine signaling as a means of regulation. Cytokines are important mediators of inter-cellular
communication. The cytokine signal is conveyed upon binding to specific surface-expressed receptors through
activation of JAK/STAT signaling pathways. However, the suppressors of cytokine signaling (SOCS) may
specifically block the generation of STAT signals from certain receptors (e.g., SOCS1 blocks induction of STAT5
upon binding of IL-7 to the IL-7 receptor [IL-7R]). The transcription of many genes depends on cytokine signaling
– for example, transcription of FOXP3 in regulatory T cells is positively regulated by STAT5 resulting from
activation of γ-chain-associated cytokine receptors (whose ligands are IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21).
Th17 cells, on the other hand, depend on signaling through STAT3 for the production of lineage-specific
transcription factors (RORα and RORγt), as well as the Th17 cytokines (IL-17A, IL-17F, and IL-21). IL-21, in
turn, reinforces the production of IL-17A and IL-17F in an autocrine or paracrine manner by binding to the IL-21
receptor. Conversely, the simultaneous generation of SOCS3 serves to inhibit signaling from the IL-6 and IL-23
receptors in a negative feedback fashion. Adapted from O’Shea et al., 2008 (290). 
have been linked to severe immunodeficiency syndromes (290). For example, mutations in 
JAK3, the gene for γc-associated kinase, or TYK2, another cytokine receptor-associated kinase 
of the Jak family, result in SCID and autosomal-recessive hyperimmunoglobulin E syndrome 
(AR-HIES), respectively (261; 284; 426). Furthermore, single-nucleotide polymorphisms 
(SNPs) in SOCS1 and SOCS3 were associated with the pathogenesis of asthma (158; 345). 
SOCS1 and SOCS3 may also be important anti-oncogenes, as hyperactivation of STAT1 or 
STAT3 has been implicated in several malignant disorders (290). 
1.3.3 Cross-talk between signaling pathways 
In the two previous chapters, a detailed account was given on the signals mediated by 
ligation of the TCR and the various cytokine receptors, respectively. However, although the 
recited cascades may appear to proceed in a linear and orderly fashion, recent technological 
advances have informed us that, in reality, this is rarely the case (123). Rather, the ligation of 
cell-surface receptors is exceedingly seen to cause the activation of multiple intracellular 
signaling pathways through extensive networking – a phenomenon known as ‘cross-talk’. 
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Figure 9 illustrates how our view of signaling has progressed from a linear perspective to a 
network-based perspective, in which different pathways interact through the use of common 
constituents. Cross-talk results from the convergence of more than one signaling pathway on 
the same signaling molecule, and serves to integrate or fine-tune the response to a number of 
concomitant stimuli, ultimately facilitating the timely induction or repression of gene 
transcription through the activation or repression of one or more transcription factors. For added 
complexity, the signaling molecule – most commonly a kinase or a phosphatase – may combine 
with other proteins to form signaling complexes with manifold targets, or it may be targeted to 
subcellular domains through the binding of specific anchoring proteins. Importantly, if the 
signaling molecule is otherwise freely diffusible, this compartmentalization may be an 
important way of diversifying the effects of a molecule that is involved in multiple signaling 
pathways. 
Cross-talk between signaling pathways constitutes an important mode of regulation 
within the cell, allowing for fine-tuning and integration of the signals that are received at the 
cell surface. The activity of a given node in a signaling network may be either positively or 
negatively regulated by the actions of other nodes, facilitating precise and quantitative 
responses to a variety of incoming stimuli. In immune-cell signaling, examples of cross-talk are 
Figure 9: On the perception of intracellular signaling. The diagram illustrates how the dogma on signaling has
progressed from a linear sequence of events to highly interactive signaling networks. Adapted from Fraser et al.,
2009 (123). 
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plentiful, and are likely to increase in numbers as the precision of our methods of detection 
improves. Figure 10 (next page) illustrates some of the signaling pathways that are currently 
known to be activated upon ligation of the TCR–CD3 complex with peptide–MHC.  Notably, a 
recent study reported using this information to predict the production of IL-2 upon a given 
stimulus (191). Thus, it is believed that if we achieve accurate knowledge of all the components 
involved in the signal triggered upon ligation of a receptor, the outcome may be predicted in a 
quantitative manner. Of course, activation under in vivo conditions will be much harder to 
interpret due to the complexity and variety of the incoming signals, for which the output will 
represent an integral that involves signals from receptors such as the TCR and its co-receptors, 
as well as various cytokine receptors and adhesion molecules. The perhaps most prominent 
instance of cross-talk in T cells results from the ligation of co-stimulatory (e.g., CD28, ICOS) 
or co-inhibitory (e.g., CTLA-4, PD-1) receptors whose intracellular signaling cascades interfere 
directly with components of the TCR signaling machinery. A logical model of TCR signaling in 
conjunction with CD28 co-stimulation in human T cells was proposed recently, involving 94 
different signaling molecules and 123 interactions (326). Such comprehensive models are 
crucial for the detection of new signaling pathways and for elucidating the relationships 
between different molecules, and may aid in understanding the development, differentiation, 
and effector functions of T cells – as well as to assess the influence of regulatory cells and 
mechanisms on these processes. 
1.3.4 Transcription and the influence of epigenetic control mechanisms 
The packaging of DNA has proved an important mechanism for regulating the 
transcriptional activity of genes and, thereby, controlling the activation status of the host cell. 
Double-stranded DNA is wrapped around histone clusters consisting of four histone pairs 
(H2A, H2B, H3, and H4), ~146 base pairs covering one cluster to create a nucleosome. The 
nucleosomes, in turn, are packed and coiled into dense chromatin fibers, rendering the DNA 
virtually inaccessible to the transcriptional machinery (181). Thus, in order to allow for the 
transcription of specific genes, the chromatin must be partly unpacked. This enables selective, 
tissue-specific regulation of transcription through structural modifications of the gene loci in 
question. The modifications involved include nucleosome repositioning, posttranslational 
modification of histone tails, and methylation of CpG dinucleotides, affecting DNA 
accessibility in a heritable manner without altering the DNA sequence itself (181). 
Epigenetic control mechanisms are believed to influence the differentiation of CD4+ T 
helper cells into either of the committed T-cell lineages, including the Th1, Th2, Th17, and 
Treg lineages (24; 181). In this context, the Ifng locus has been intensely studied and represents 
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an impressive example of epigenetic regulation. Notably, phylogenetic studies have revealed a 
stretch of DNA flanking both sides of the human IFNG locus that spans more than 150 000 
base pairs and contains a high degree of evolutionarily conserved non-coding sequences (NCS). 
The order, as well as the 5’-3’ orientation, of these NCS were absolutely conserved (368). The 
fact that these sequences are conserved across distant species indicates that they serve important 
functions in the transcription of the Ifng gene. Thus, it was later recognized that NCS widely 
distributed across the Ifng locus were modified by the activating process of histone H4 
acetylation, promoting Ifng gene expression (461). Histone H4 acetylation across the entire Ifng 
locus was dependent on STAT4 in a Th1 differentiation system driven by IL-12 (77). The 
transcription factor T-bet is known to bind several of the NCS across the Ifng locus, yet has so 
far only been shown to mediate H4 acetylation in one (77; 165). In addition, this master 
regulator of Th1 development was found to induce chromatin remodeling in the Ifng locus of 
mice (384) although, apparently, this was not an absolute requirement for Th1 differentiation 
(402). Hence, with respect to regulating nucleosome organization, STAT4 has actually proven 
more potent than T-bet (452). 
Another set of histone modifications were found in the Ifng locus upon differentiation of 
naive CD4+ T cells along the Th2 pathway. The recruitment of STAT6 and GATA-3 to the Ifng 
locus of murine T cells resulted in the generation of repressive H3K27-dimethylation and 
trimethylation marks rather than the activating acetylation marks mentioned previously, 
efficiently silencing Ifng in Th2 cells. At the same time, however, STAT6 and GATA-3 
mediate transcriptional activation of the Il4 
locus by the widespread introduction of 
activating histone modifications, leading to 
transcription of the Il4 gene. How this 
selectivity in mediating epigenetic 
modifications is achieved remains to be 
Figure 10: Signal networking in T cells. Ligation of
the TCR–CD3 complex in conjunction with CD4
results in activation of an extensive signaling
network. Provided exhaustive knowledge of the
ensuing processes, models of the network may be
used to predict its outcomes. One isolated process that
has been tested in this respect is the activation of the
IL-2 promoter and transcription of the cytokine IL-2.
Adapted from Kemp et al., 2007 (191). 
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elucidated, but may result from the differential expression of specific binding sites for the 
respective transcription factors (24). 
Very recently it was suggested that, similar to the Th1- and Th2 lineage transcription 
factors, the master regulator of Treg, FOXP3, could mediate some of its effects through 
transcriptional repression of target genes (296). Apparently, it does so by recruiting the 
transcription factor Eos, which induces chromatin modifications in target genes through 
association with the carboxy (C-) terminal binding protein-1 (CtBP1), a known repressor of 
gene expression. The FOXP3–Eos–CtBP1 suppression complex was found to target a number 
of genes – including the IL-2 gene – which were silenced by the combined effects of histone 
modifications and methylation of CpG dinucleotides. The putative relevance of Eos for the 
suppressive function of Treg was confirmed by in vitro proliferation assays, as well as in an in 
vivo model of colitis (296). Of note, Eos did not affect the expression of genes that were up-
regulated by FOXP3, thus causing only partial conversion of Treg into effector T cells (Teff) 
when silenced by small interfering RNA (siRNA)-mediated knockdown. Notably, however, the 
in vitro suppressive capacity of Treg was lost in the absence of Eos (296). View Section 1.4 for 
a more detailed account of Treg. 
1.4 Regulatory T cells 
1.4.1 The suppressor cell 
The suppressor cell was first described by Gershon and Kondo in 1970 (138). They had 
identified a population of T cells that were different from the helper T cells and served to 
dampen immune responses. This was an astonishing observation, and in the following years the 
suppressor cells were intensely studied. Early investigations of the suppressor cells led to a 
series of findings that seemed to corroborate their existence. For example, as previously 
mentioned, studies in thymectomized mice revealed that neonatal thymectomy (nTx) between 
the second and fourth days of life led to T-cell mediated lesions that could be reversed by the 
administration of T cells from adult euthymic mice (282; 331). These experiments 
demonstrated that a population of T cells generated after 3 days of life mediated dominant 
immune tolerance. However, research on suppressor cells stagnated in the 1980s, primarily due 
to a lack of methodologies sensitive enough to obtain reliable information about these cells, but 
also due to the absence of any distinctive surface marker that could be used to isolate and purify 
them (332). Furthermore, it was deemed a serious setback that the I-J chain, which was 
supposed to be key to the suppressive function of these cells, was found not to exist (210). Only 
in 1995, with the identification of a suppressive subset of T cells expressing the IL-2 receptor α 
31 
chain (CD25), did the suppressor cell resurface – this time under the untainted name 
“regulatory T cell” (330). The seminal study performed by Sakaguchi and colleagues showed 
that CD4+ T cells depleted of CD25+-expressing cells caused autoimmune disease when 
transferred into nude mice, and that CD4+CD25+ T cells (i.e., regulatory T cells) could reverse 
the autoimmune reaction. 
Although important for the initial discovery of Treg, CD25 represents a suboptimal 
marker for Treg as it is expressed on other T-cell subsets as well, including activated effector T 
cells. In this respect, the discovery of the X chromosome-encoded gene FOXP3, which was 
identified while looking for the underlying cause of the IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked) syndrome in humans and the spontaneous murine 
mutant scurfy (37; 62; 78; 430), has been pivotal in progressing our understanding of the Treg 
biology. Following its discovery, stable expression of FOXP3 was shown to be restricted to 
Treg, and the differentiation and suppressive function of Treg was shown to rely on this 
transcription factor (121; 122; 134; 174; 194; 237). Furthermore, the sustained expression of 
FOXP3 was required for maintaining the anergic phenotype and suppressive capacity of mature 
Treg, and the loss of FOXP3 resulted in acquisition of effector T-cell properties such as the 
production of pro-inflammatory cytokines like IL-2, IL-4, IL-17, and IFN-γ (423; 432). 
Recently, however, the role of FOXP3 as the “master regulator” responsible for empowering 
Treg with suppressive functions has been questioned. Firstly, subsets of Treg have been 
identified that do not express this canonical Treg marker, most importantly the antigen-specific 
and IL-10-secreting Tr1 cells (412). Secondly, not all T cells that express FOXP3 have 
suppressive capabilities – in fact, some studies suggest that FOXP3 is up-regulated following 
normal TCR stimulation, and that the resulting phenotype is neither anergic nor suppressive 
(135). Even so, FOXP3 remains the most specific Treg marker, yet its intracellular expression 
limits its uses. A surface-expressed marker, on the other hand, could be used to specifically 
identify and isolate Treg and would be of substantial importance in promoting further studies of 
Treg subsets. So far, however, none of the suggested markers – including CTLA-4, GITR, 
CD38, CD5, low-level CD127, and so on – have been Treg-specific, and the phenotype initially 
put forth by Sakaguchi and colleagues (CD4+CD25+) remains the gold standard. Consequently, 
we still do not have a unique marker that can be used to unambiguously distinguish between 
Treg and effector T cells. 
1.4.2 Natural and inducible subsets of regulatory T cells 
The Treg initially described by Sakaguchi and colleagues were generated in the thymus, 
and have come to be known as ‘natural’ Treg (nTreg). They are recruited during the thymic 
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selection and maturation process as a result of high-avidity MHC class II-dependent TCR 
interactions, and play a central role in maintaining tolerance and preventing autoimmunity 
(329). Only in recent years has the generation of ‘induced’ Treg (iTreg) in peripheral tissues 
been appreciated. As it was recognized that expression of CD25 was a prerequisite for Treg 
functionality (131), Curotto de Lafaille and colleagues in 2004 demonstrated peripheral 
expansion of CD25+FOXP3+ Treg in mice (96). The year after, Knoechel and colleagues 
formally established that peripherally induced Treg were independent of the thymus, seeing that 
they could be induced in thymectomized animals (201). In the following years, the minimal 
requirements for generation of iTreg were shown to include activation through the TCR as well 
as expression of the cytokines TGF-β and IL-2 (95). Using protocols that include these factors 
has enabled generation of Foxp3+ iTreg both in vivo and in vitro, although numerous reports of 
failed attempts to do so underline our limited understanding of this process so far (95). 
In contrast to the highly controlled thymic environment fostering the generation of nTreg, 
iTreg are generated under the more varied conditions within peripheral tissues. Their primary 
task appears to be the induction of tolerance to commensal bacteria and food allergens in the 
gut, thereby maintaining a non-inflammatory environment. In addition, they may interfere with 
immunity against viruses, bacteria, and parasites, possibly contributing to the development of 
chronic infections. They have also been shown to accumulate at tumor sites, where they may 
impair the development of effective anti-tumor immune responses (241). The possibility that 
nTreg and iTreg may have shared or overlapping tasks has received some attention lately, since 
a scenario with partially redundant Treg could have therapeutic consequences. Were indeed 
such redundancies identified, one Treg population could be used to treat diseases caused by 
deficiencies of another. Thus far, firmly overlapping functions of iTreg and nTreg have not 
been identified – mainly due to a lack in lineage-specific markers. However, using a colitis 
transfer model, Haribhai and colleagues (160) demonstrated that iTreg played an important role 
in protecting against colitis, and that a combination of nTreg and iTreg was necessary to protect 
from this disease. Hence, nTreg and iTreg may synergize to achieve optimal regulation, at least 
in some instances. Notably, the distinct origins of nTreg and iTreg and their inherent 
differences (such as distinct TCR repertoires) support the notion that they also serve different 
tasks (Fig. 11) (95). 
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Figure 11: FOXP3+ Treg may be generated in the periphery as well as in the thymus. Whereas natural Treg
(nTreg) are generated in the thymus in the course of T-cell maturation, Treg are also induced in the secondary
lymphoid tissues of the periphery (including lymph nodes, spleen, and gut-associated lymphoid tissues [GALT]),
as well as in inflamed tissues. Thus, the total pool of FOXP3+ Treg includes both nTreg and peripherally induced
Treg (iTreg). It is likely that these two subsets have distinct TCR repertoires. In addition, peripheral FOXP3- Treg
populations (Tr1 and Th3) have been described. Some activated T cells may express FOXP3 even though they are
not suppressive. Adapted from Curotto de Lafaille et al., 2009 (95). 
1.4.3 Suggested modes of action 
Regulatory T cells are critically involved in maintaining peripheral tolerance, and a 
number of suppressive mechanisms have been suggested to that end. Typically, these 
mechanisms have been identified and tested using in vitro model systems, and their roles in vivo 
may not yet have been established. One important dichotomy has become clear, though: The 
Treg may either suppress the effector T cells directly, or they may act on APCs or other 
accessory cells to indirectly influence the activation status of the effector T cells (Fig. 12). 
Modes for the direct suppression of T cells may be either contact-dependent or mediated 
by soluble factors (see Fig. 12). Hence, four different possible approaches have been identified: 
1) The secretion of suppressor cytokines; 2) IL-2 consumption; 3) granzyme-mediated 
cytolysis; and 4) the expression of membrane-bound or soluble inhibitory molecules (350). 
Only iTreg have thus far been demonstrated to mediate suppression through the secretion of 
suppressor cytokines, of which IL-10 and TGF-β are the best characterized. In Paper 1, we have 
demonstrated the suppressive capacity of IL-10-secreting HIV-1-specific T cells. Similar to the 
previously mentioned Tr1 cells they may suppress target cells through the secretion of IL-10, 
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though this question was not addressed in the present work. Natural Treg, on the other hand, 
normally require cell-to-cell contact in order to be suppressive. Recently, however, the 
inhibitory cytokine IL-35 was found to contribute to nTreg-mediated suppression in mice. Its 
relevance was substantiated by the finding that IL-35 expression is regulated by Foxp3 (91). 
However, in human nTreg, the expression level of IL-35 appears to be too low to mediate 
significant suppression (27). Galectin-1 is a membrane-bound β-galactoside-binding protein 
that binds to many glycoproteins (e.g., CD7, CD43, and CD45) and may confer nTreg-mediated 
suppression either as a soluble homodimer, or while presented on the plasma membrane. 
Interestingly, galectin-1 is up-regulated in nTreg and induced upon TCR activation, and in a 
recent study the suppressive capacity of both human and murine nTreg was reduced upon 
galectin-1 blockade (132). 
The components of the high-affinity IL-2 receptor – CD25, CD122, and CD132 – are all 
expressed by Treg, and IL-2 is essential both to Treg homeostasis in vivo (448) and for their 
suppressive function in vitro (393). Thus, it has been speculated – and shown in a recent study 
(297) – that Treg could mediate their suppression through this receptor, possibly by tethering 
IL-2 and thereby depriving neighboring T cells of important survival cues and imposing cell-
cycle arrest. However, other studies rather suggest that Treg inhibit the IL-2 production of 
responder cells (30; 102; 365). Furthermore, it was recently shown in a hybrid system using 
human Treg and murine effector T cells that blocking of the high-affinity IL-2 receptor with 
antibodies specific for human CD25 did not affect suppression (397). Yet another putative 
suppressive mechanism involves Treg-mediated cytolysis of target cells. This may be achieved 
by the upregulation of granzymes, as demonstrated in several studies of murine as well as 
human cells (145; 149; 455). In a recent study in mice, about 5-30 % of tumor-associated Treg 
were found to express granzyme B, and these were able to kill natural killer (NK) cells and 
cytotoxic T lymphocytes (CTLs) in a granzyme B- and perforin-dependent manner (71). 
The Treg have been shown to act – in the manners mentioned above – on CD4+ or CD8+ 
T cells, directly affecting the effector functions and proliferative capacity of these cells (83; 
306; 386). However, Treg may also operate indirectly by inhibiting the maturation of DCs or by 
interfering with antigen presentation (262). Thus, the Treg have demonstrated a wide array of 
target cells, from the CD4+ and CD8+ T cells via DCs, B cells, NK and natural killer T (NKT) 
cells to macrophages, osteoblasts, and mast cells (140; 235; 327; 350; 363; 416). Suppressive 
mechanisms directed against APCs are of considerable interest, since any APC may potentially 
activate several T cells. In other words, targeting one APC may be the equivalent of targeting 
multiple T cells. An array of suppressive mechanisms have been suggested that target the APC 
– here represented by DCs: 1) Modulation of DC maturation stage; 2) DC arrest at the immature 
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stage; 3) inactivation of extracellular adenosine tri-phosphate (ATP); 4) obstruction of T-cell 
priming. Several studies have demonstrated the ability of Treg to down-regulate the expression 
of co-stimulatory molecules on DCs (262; 346). In some studies, Treg-mediated inhibition of 
DCs could be reversed by anti-CTLA-4 treatment, indicating that ligation of CTLA-4 to the 
DC-expressed CD80 and CD86 was responsible for the inhibition (293; 350). Correspondingly, 
treatment of mice with anti-CTLA-4 abrogated Treg-mediated suppression of inflammatory 
bowel disease (IBD) (316), though perhaps the most convincing piece of evidence so far was 
obtained in mice that were selectively deleted for Treg-expressed CTLA-4, which developed 
systemic autoimmunity at 7 weeks of age (433). 
A recently identified mechanism of DC-modulation by Treg involves the ligation of Treg-
expressed LAG-3 (CD223) to MHC class II molecules expressed by immature DCs, initiating 
an inhibitory signal that prevents maturation of the DC and inhibits its immunostimulatory 
Figure 12: Suggested modes of suppression for regulatory T cells. Regulatory T cells (Treg) may inhibit the
activation, effector function, or proliferation of effector T cells through one or several mechanisms of suppression.
The different suppressive modes may be separated into direct (left, blue rim) or indirect modes (right, pink rim) of
suppression. The direct modes, which may or may not depend on cell-to-cell contact, include the secretion of
suppressor cytokines (top left), IL-2 consumption, cytolysis, and inhibition through surface-bound molecules
(bottom left). The indirect modes operate through modulation of various accessory cells (typically antigen-
presented cells, like the dendritic cells shown here). Indirect mechanisms of suppression that have thus far been
described include the actions of CTLA-4 (top right), CD39, LAG-3, and Nrp-1 (bottom right), respectively. 
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capacity (234). Another putative inhibitory mechanism involves the ectoenzyme CD39, which 
is expressed by B cells, DCs, all murine Treg, and approximately 50 % of human Treg (52). 
CD39 serves to hydrolyze extracellular ATP or adenosine diphosphate (ADP) to adenosine 
monophosphate (AMP), effectively neutralizing ATP-driven inflammation. The subsequent 
conversion of AMP to adenosine by Treg-expressed CD73 may further amplify the anti-
inflammatory effect via A2a receptors on effector T cells (103). Furthermore, formation of 
long-lasting Treg–DC conjugates that interfere with the priming of self-reactive T cells may 
constitute a suppressive mechanism to prevent autoimmunity (387). In this respect, neuropilin 
(Nrp-1) was recently identified a Treg-associated molecule that is induced upon Foxp3 
expression, and that mediates long interactions between Treg and immature DCs in conditions 
with limited antigen (337). Hence, Treg may prevent T-cell activation by blocking the 
interactions between naive T cells and DCs in an obstructive manner. 
Very recently, a new paradigm has entered the stage, by which Treg are said to selectively 
suppress certain T helper cell lineages depending on the cytokine milieu. In essence, the new 
dogma states that Treg are differentiated into lineages in a manner similar to the T helper cells, 
and that cytokines directing the differentiation of specific T helper cells may simultaneously 
induce Treg that specifically suppress the corresponding T helper lineage. In three recent 
publications, lineage-specific Treg have been identified that target Th1 (202), Th2 (457), and 
Th17 (79) cells, respectively. In addition to FOXP3, these Treg express lineage-specific 
transcription factors that reportedly play a central role in their suppressive actions, namely T-
bet (Th1), interferon regulatory factor-4 (IRF4; Th2), and STAT3 (Th17). Importantly, the 
generation of lineage-specific Treg was shown to be instrumental in controlling immune 
responses and limiting immune pathologies in murine disease models (79; 202; 457). At 
present, the corresponding mechanisms in humans remain to be established. 
1.4.4 The balance between Treg and Th17 cells 
The link between Treg and Th17 cells is evident from the transcriptional regulation of 
these cells. While FOXP3 is the lineage-specific transcription factor of Treg and RORγt is 
required and sufficient for Th17-cell differentiation, double-positive FOXP3+RORγt+ T cells 
have also been identified (418; 460). The FOXP3+RORγt+ T cells secrete lower levels of IL-17 
than the single-positive FOXP3-RORγt+ T cells, indicating that FOXP3 inhibits RORγt-
induced IL-17 expression in a cell-intrinsic manner (460). Correspondingly, FOXP3 deficiency 
results in increased IL-17 expression without affecting the levels of RORγt (134). Depending 
on the cytokine environment, cells co-expressing FOXP3 and RORγt may differentiate into 
either Th17 or Treg cells. Differentiation to the Th17 lineage is favored by the presence of pro-
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inflammatory cytokines (IL-6, IL-21, or IL-23), whereas low levels of these cytokines and high-
level expression of TGF-β shift the balance towards differentiation of Treg (460). The 
differentiation of Treg is further enhanced by the presence of IL-2 and retinoic acid (RA), both 
of which inhibit the expression of RORγt and augment TGF-β-mediated FOXP3 expression 
(92; 220; 270; 377). 
The recently discovered Th17 cells produce the pro-inflammatory cytokine IL-17 and are 
thought to be important in the pathogenesis of autoimmune and inflammatory disorders (206; 
413). Similarly to the iTreg, Th17 operate predominantly in the mesenteric lymph nodes and 
Peyer’s patches. It was recently shown that the cytokine TGF-β plays a role in regulating the 
differentiation of Th17 cells (41; 249; 410). This was rather surprising, since the same cytokine 
controls the generation of iTreg and provides nTreg with survival cues after their exit from the 
thymus (84; 232; 251). Interestingly, mice that do not express TGF-β lack both FOXP3+ Treg 
and Th17 cells, and suffer severe autoimmunity, largely due to uncontrolled Th1 cell activity 
(231; 410). Thus, it appears that an intimate relationship exists between Treg and Th17 cells – a 
notion that is further substantiated by the recent identification of intestinal CD4+ T cells in 
mice as well as humans that simultaneously express both FOXP3 and the Th17 lineage-specific 
transcription factor RORγt, and that produce IL-17, albeit at levels below the bona fide FOXP3-
RORγt+ Th17 cells (460). Moreover, two recent studies demonstrated a relationship between 
the microbiota of the gut and the abundance of Th17 cells – which was shown to be inversely 
correlated with the abundance of FOXP3+ Treg (22; 179). In this respect, the microbial 
expression of different sets of PAMPs that activate distinct PRRs has been suggested to skew 
the balance between the regulatory Treg and the pro-inflammatory Th17 cells, and between 
tolerance and inflammation (312). In a series of knockout studies, a higher Treg frequency was 
observed in the intestinal tissues of mice deficient for TLR9 (155), whereas TLR2-deficient 
mice had reduced numbers of Treg (381). The abundance of Treg in TLR9-deficient mice was 
accompanied by a reduction in the numbers of Th17 cells (155). Thus, activation through TLR9 
may serve to shift the balance towards Th17 cell differentiation, which in the presence of TGF-
β fosters an inflammatory Th17 response. 
1.4.5 FOXP3-negative Treg 
The IL-10-secreting Tr1 cells are distinct from nTreg as well as iTreg in that they do not 
express the transcription factor FOXP3 (412). This regulatory subset is otherwise defined by 
their secretion of high levels of IL-10 and TGF-β in response to cognate antigens, and their 
ability to suppress antigen-specific activation of effector T cells in a cytokine-dependent 
manner (320). The suppressive capacity of Tr1 cells was first appreciated by Groux and 
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colleagues in 1997, as they were able to isolate clones of IL-10-secreting CD4+ T cells 
following chronic allogeneic activation of murine cells in the presence of IL-10 (151). 
Importantly, the isolated Tr1 cells were shown to suppress a pathological immune response in 
vivo by preventing experimentally induced colitis in severe combined immunodeficiency 
(SCID) mice (151). Tr1 or Tr1-like cells may be induced in a variety of ways, and the different 
experimental conditions may generate cells of slightly different phenotypes (8-10; 28; 56; 187; 
288; 378; 379; 412). As no specific marker for Tr1 cells has currently been identified, their 
identification relies on assessment of their suppressive capacity and cytokine profile. 
The suppressive actions of Tr1 cells have been ascribed to their secretion of the 
immunoregulatory cytokines IL-10 and TGF-β (25; 28; 151; 224; 411). This mode of action 
entails non-specific regulation, termed ‘bystander suppression’, which is in contrast to their 
antigen-specific TCR-dependent induction (150). The fact that the Tr1 cells may be induced 
from naive cells upon prolonged exposure to antigen suggests that they are part of the adaptive 
immune response, and that they contribute to the maintenance of peripheral tolerance upon 
chronic immune activation (320). The possible implications of Tr1-like cells in HIV-infected 
individuals were studied in Paper 1. 
The Th3 cells constitute another subset of FOXP3-negative Treg, distinguishable by their 
ability to produce TGF-β. They were initially isolated from the lymphoid tissues of mice that 
were fed low doses of antigen, and are believed to mediate oral tolerance (85; 127; 429). 
Similar to Tr1 cells, they mediate their suppression through the secretion of inhibitory 
cytokines; most notably TGF-β, but also some Th2 cytokines (IL-4 and/or IL-10) that may 
impede the differentiation and activation of Th1 cells (85; 429). Notably, anti-TGF-β treatment 
can inhibit several aspects of oral tolerance (157; 277; 428). 
1.5 Immunomodulatory roles of the second-messenger cAMP 
Cyclic AMP belongs to the cyclic nucleotide family of second messengers, ‘second 
messenger’ signifying a molecule transmitting an intracellular signal following ligation of the 
‘first messenger’ to a cell-surface receptor. In the case of cAMP, the ‘first messenger’ denotes 
any ligand capable of activating adenylyl cyclase (AC) through binding to a G protein-coupled 
receptor (GPCR) that is linked to a stimulatory G protein α-subunit (Gαs), resulting in the 
conversion of ATP to cAMP (307). Cyclic AMP regulates a host of cellular processes, and 
subcellular localization is absolutely crucial for maintaining the specificity of its actions. This 
is, to a large extent, achieved by the site-specific operations of more than 50 isoforms of cAMP 
phosphodiesterases (PDEs), which serve to rapidly hydrolyze cAMP, restricting and eliminating 
local cAMP pools unless a continuous production is maintained by nearby activated ACs. Some 
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specificity may also be afforded by the nine different isoforms of AC (Fig. 13), all of which 
have different regulation and expression patterns (308). The stringency of cAMP control 
explains how cAMP can serve so many different signaling functions simultaneously. 
Cyclic AMP has four known cellular effectors; protein kinase A (PKA) type I and II, 
guanine nucleotide exchange protein directly activated by cAMP (EPAC), and cAMP-gated ion 
channels (Fig. 14), of which the two PKA isoforms have traditionally played a leading role 
(34). Over the last decade, however, numerous cAMP-driven cellular processes that are 
independent of PKA have been identified, several of which are regulated by EPAC (334). 
Cyclic AMP positively regulates the transcription of cAMP-responsive genes through the 
activation of the transcription factors cAMP response-element (CRE)-binding protein (CREB), 
cAMP response-element modulator (CREM), and activator transcription factor (ATF)-1, all of 
which belong to the basic-leucine zipper class of transcription factors (334). CREB recruits 
CREB-binding protein (CBP) upon phosphorylation on serine 133 by PKA, thereby enabling 
the binding to CREs. The alternative splicing of primary transcripts from the CREB and CREM 
genes serves to generate factors capable of repressing target gene expression, as opposed to the 
activating properties of the full-length proteins (263; 323; 420). Of note, one of the splice 
variants of CREM, known as inducible cAMP early repressor (ICER), was demonstrated to be 
of particular importance to the negative regulation of CRE-mediated transcription (263). The 
expression of ICER is regulated by an alternative, intronic CREM promoter containing four 
closely spaced CREs in tandem that is strongly induced by cAMP. De novo synthesized ICER 
represses the transcription of genes by binding to CREs in their promoter, and, similarly, 
autoregulates itself by tethering to the clustered CREs of its own promoter, which are therefore 
called cAMP autoregulatory elements (CARE) (263). 
Figure 13: Restricted expression of components of the
cAMP–PKA signaling machinery. Both adenylyl cyclases
(ACs; pink circles) and A-kinase anchoring proteins (AKAPs;
yellow circles) have restricted expression in humans. In
addition, the tissue distribution of the cAMP
phosphodiesterases (PDEs) and the different isoforms of PKA
further contribute to the specificity in cAMP signaling. 
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Figure 14: The second-messenger cAMP. Cyclic AMP (cAMP) is generated by adenylyl cyclases (ACs), which
are regulated by inhibitory and stimulatory G-protein-coupled receptors (GPCRs). The cAMP phosphodiesterases
(PDEs) negatively regulate cAMP-levels and serve to maintain distinct cAMP pools. The effects of cAMP are
mediated through four cAMP-sensitive effector proteins; PKA type I and II, Epac, and cAMP-gated ion channels. 
Presently, most of the immunoregulatory effects of cAMP appear to be mediated through 
PKA, which will be discussed below. The cAMP-gated ion channels have no known function in 
the immune system, but should not be disregarded at this point since the field of cAMP 
signaling is far from exhausted, and new modes of action are likely to be discovered. In this 
respect, the recent development of EPAC-selective cAMP analogs (173) will certainly expand 
our knowledge on the non-redundant functions of EPAC, of which some could also be of 
relevance to immune function. As a matter of fact, EPAC has already proven itself an 
immunoregulator in macrophages and dendritic cells by inhibiting phagocytosis, microbicidal 
activity, and the generation of inflammatory mediators upon activation by cAMP (19; 20). 
Finally, the recent development of a method for real-time detection of cAMP (40) should 
reinforce the many ongoing investigations regarding the pluripotency of this second messenger. 
1.5.1 The cAMP-dependent protein kinase 
Protein kinase A (PKA) – also known as the cAMP-dependent protein kinase – is a 
ubiquitously expressed serine/threonine kinase of broad substrate specificity. The tetrameric 
holoenzyme consists of two catalytic subunits that are maintained in an inactive conformation 
by a regulatory subunit dimer. The kinase is activated by the consecutive binding of two cAMP 
molecules to each of the regulatory subunits, inducing conformational changes that serve to 
release the enzymatically active catalytic subunits. Three isoforms of the catalytic subunit exist 
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(Cα, Cβ, Cγ), as well as four different isoforms of the regulatory subunit (RIα, RIβ, RIIα, RIIβ). 
The resulting PKA isoforms (designated type I or type II PKA depending on the nature of their 
regulatory subunit dimer) perform non-redundant actions and are distinctly distributed 
throughout the cell by specifically tethering to certain A-kinase anchoring proteins (AKAPs) 
via the dimerization and docking (D/D) interface of their regulatory subunit dimer (104; 106). 
Thus, the AKAPs afford an important degree of specificity to cAMP-dependent signaling by the 
docking of PKA (and EPAC) to localized subcellular domains. In addition, the scaffolding 
nature of AKAPs facilitates co-localization of PKA with its substrates, as well as with 
phosphatases and PDEs that may serve to terminate the signal (391). Notably, the fact that PKA 
signaling relies on sub-cellular targeting has been exploited while studying the relevance of the 
respective isoforms in various cellular systems by employing anchoring disruptor peptides like 
the RI anchoring disruptor (RIAD) (72) and SuperAKAP-in silico (SuperAKAP-IS) (143) that 
specifically disrupt the anchoring of PKA type I and PKA type II, respectively. Moreover, the 
wish to study PKA functions in vivo has now led to the development of anchoring disruptor 
peptidomimetics that are resistant to enzymatic proteolysis (see Paper 2 of this Thesis). 
PKA, and in particular PKA type I, has been implicated at several levels in immune 
regulation and is known to regulate various aspects of T-cell activation (341; 396), as illustrated 
in Figure 15. A transient increase in cAMP levels has been reported in lymphocytes upon 
antigen receptor stimulation, which could signify activation of the intracellular cAMP receptors 
(215; 216; 222). Several reports have indeed suggested a role for PKA in the modulation of 
proximal TCR signaling (80; 200; 300; 322), and PKA type I has been shown to co-localize 
with the capped TCR following its activation (359; 462). In addition, CREs have been 
identified in the TCR and CD3 genes, as well as in several other genes associated with 
lymphocyte activation, which could potentially be regulated by PKA (16; 152). These and other 
studies point to a physiological role of PKA in T-cell activation. PKA type I is known to inhibit 
T- and B-cell proliferation (226; 358), and may also affect NK-cell cytotoxicity (395). 
Moreover, PKA has been deemed an important regulator of innate immunity by affecting 
multiple functions of macrophages as well as dendritic cells (19; 342; 421). So far, in vivo data 
on the immunological effects of PKA is limited to observations in the RIIα-/- knockout mouse, 
in which no marked effects on immune function were seen. Corresponding studies in RIα-/- 
knockout mice were hindered by the embryonic lethality of this genotype (340). We do know, 
however, that ablation of the Cα subunit causes immune cell hyperresponsiveness, indicating 
non-redundant immune-regulatory functions of PKA isozymes carrying the Cα subunit (130). 
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 Figure 15: Multiple substrates of PKA in T cells. PKA has been shown to phosphorylate a number of proteins
involved in TCR signaling, which points to a potential role in modulating the activation, differentiation, and/or
proliferation of T cells. Adapted from Torgersen et al., 2002, and Shillace et al., 2006 (341; 396). 
1.5.2 A-kinase anchoring proteins 
The ubiquitous expression of cAMP and the abundance of PKA substrates invoke 
assistance from extrinsic mechanisms for subcellular targeting and signal specificity. Thus, 
although PKA (as well as the ACs and PDEs) exists in several isoforms, and the diffusion of 
cAMP may be limited by cellular structures, one has increasingly appreciated the role of the A-
kinase anchoring proteins (AKAPs) for maintaining fidelity in the actions of cAMP and PKA 
(40; 119; 361). Indeed, the more than 30 known mammalian members of the AKAP family are 
themselves distinctly distributed in a tissue-dependent manner (73). However, the role of 
AKAPs in mediating specific cAMP signaling is tightly linked to their ability of co-localizing 
the cAMP effectors (most prominently PKA) along with their respective substrate molecules. 
Recent findings indicate that AKAPs are also capable of recruiting the cAMP-generating ACs 
to the molecular scaffold – as well as GPCRs that may activate the ACs – and PDEs that 
degrade cAMP into AMP, thereby providing a precise constellation for the control of local 
cAMP levels. The activity of associated ACs may be further regulated through phosphorylation 
or dephosphorylation by kinases and phosphatases present in the scaffold. Similarly, the activity 
of PKA may be regulated in a feedback fashion through dephosphorylation by associated 
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Figure 16: The different AKAPs tether specifically a
certain combination of proteins, including one or more
adenylyl cyclases (ACs); cAMP receptors such as PKA
and/or EPAC; cAMP-degrading phosphodiesterases
(PDEs); PKA substrates including different protein kinases
(PKs); and signal inhibitory molecules such as protein
phosphatases (PPs). The AC is normally activated by an
associated G-protein coupled receptor (e.g., adrenergic
receptors). The AKAP may also tether other membrane-
bound receptors or ion channels, and constituents of the
scaffold may influence AC activity (325; 391). 
phosphatases or as a result of PDE-mediated cAMP depletion. Some of the attributes of AKAP-
mediated scaffolding complexes are illustrated in Figure 16. 
The AKAPs bind PKA through a helical A-kinase-binding (AKB) domain that tethers the 
dimerization/docking (D/D) domain of the regulatory subunit dimer of PKA (66). The D/D 
domain forms a groove between the two R subunits, the conformation of which differs between 
PKA type I and PKA type II and determines the specificity of the AKAP for either of the two 
PKA isozymes (26; 278). This forms the basis for isotype-specific anchoring disruption, which 
has successfully been achieved with the RIAD (for PKA type I) and SuperAKAP-IS (for PKA 
type II) peptides. In Paper 2, we have developed stabilized analogs of the RIAD peptide that 
may facilitate pharmacological studies of PKA anchoring disruption in vivo. 
1.5.3 The cAMP–PKA–Csk inhibitory pathway 
As outlined in the previous chapter, several of the signaling pathways that facilitate T-cell 
activation may be influenced by PKA, including the signaling of the TCR itself and its various 
co-receptors. This chapter will focus mainly on the effects of PKA on proximal TCR signaling, 
which has attracted considerable interest over the past years, and which constitutes an important 
part of our lab’s work. Notably, when it comes to regulating T-cell activation, the TCR 
signaling cascade is pivotal and perhaps the most relevant to target. 
In T cells, the majority of PKA (70-80 %) are of the type I isoform (RIα2C2), whereas 
about 20 % constitute type II (RIIα2C2) PKA (104). While most of the type II PKA is 
particulate (i.e., is associated with intracellular organelles), PKA type I is found predominantly 
in cytosol, and has the propensity to translocate to lipid rafts and co-localize with the TCR upon 
T-cell activation (104; 409; 462). The targeting of PKA type I to lipid rafts was originally 
thought to depend on the AKAP ezrin (4; 322), though recent evidence indicate a certain degree 
of functional redundancy conferred by moesin, the other member of the ezrin, radixin, and 
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Figure 17: Specific displacement of PKA type I relieves the inhibitory tonus imposed on proximal TCR signaling
by the cAMP–PKA–Csk pathway. PKA type I is targeted to the immunological synapse by the A-kinase anchoring
protein (AKAP) ezrin (upper panel). In the presence of cAMP, activated PKA type I phosphorylates and activates
Csk, which in turn inhibits Lck by phosphorylating its inhibitory Tyr505 residue. This results in inhibition of
proximal T-cell receptor (TCR) signaling. The RI anchoring disruptor (RIAD) peptide may restore TCR signaling
by specifically displacing PKA type I from the immunological synapse by blocking its interaction with Ezrin. 
moesin (ERM) family present in T cells (177; 347). Ezrin also serves to co-localize anchored 
PKA with its substrate Csk through binding of Cbp/PAG (322). Once in lipid rafts, PKA 
activates Csk by phosphorylating its serine 364 residue, whereupon Csk phosphorylates the C-
terminal inhibitory residue (tyrosine 505) of Lck (409). This renders Lck inactive, thereby 
inhibiting the proximal step of TCR-signaling, which involves Lck-mediated phosphorylation 
of the TCR ζ-chains (374). Thus, PKA type I is involved in the regulation of proximal TCR 
signaling (see Fig. 17, top panel). 
Different approaches were employed in establishing PKA type I as a mediator of TCR-
proximal regulation, including the isoform-specific cAMP analogs, which were central to the 
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discovery of the cAMP–PKA–Csk pathway (358). Recently, RIAD was introduced as another 
tool for delineating the isoform-specific effects of PKA in T cells (322). However, the original 
RIAD peptide was not sufficiently stable to be used in vivo. Therefore, in the present Thesis 
(Paper 2), a substitution strategy using unnatural amino acids was employed to improve the 
stability of RIAD through the introduction of unnatural amino acids. The resulting 
peptidomimetics were shown to have a 50-fold increase in serum stability compared to RIAD, 
which should be sufficient for their use in vivo. Figure 17 (bottom panel) illustrates how the 
newly designed anchoring disruptors (represented by RIAD) are envisioned to interrupt 
proximal T-cell signaling by disrupting the anchoring of PKA type I. 
1.5.4 Prostaglandin E2 
The prostanoids, including the biologically active prostaglandins PGD2, PGE2, PGF2, and 
PGI2, as well as thromboxane A2, are all diverted from the membrane lipid arachidonic acid 
(357; 406; 407). The rate-limiting step of their synthesis is governed by the cyclooxygenases 
(COX), of which two isozymes exist: COX-1 is constitutively expressed in most tissues, and the 
output of this isozyme is considered to fulfill mostly homeostatic functions. In contrast, the 
expression of Cox-2 is inducible upon a variety of stimuli, including inflammation, injury, and 
growth factor stimuli (357; 406; 407). Notably, it is the inducible Cox-2 isozyme that is 
responsible for most of the symptomatic PG production, causing inflammation, pain, and fever. 
PGE2 is the most prominent prostanoid with respect to immunomodulatory functions, and 
has been known for a long time to suppress Th1 differentiation by increasing the intracellular 
cAMP concentrations (3; 42; 142; 146; 163). A study assessing the immunosuppressive actions 
of PGE2 in knockout mice for each of the four PGE2 receptors (EP1-EP4) identified EP2 and 
EP4 as the receptors responsible for PGE2-mediated immune suppression (275). However, two 
recent studies found treatment with PGE2 to promote inflammation through Th1 differentiation 
and expansion of Th17 cells (48; 440). The effect on Th1 differentiation was assigned 
activation of PI3K, whereas the Th17 cells were expanded in a PKA-dependent manner. These 
were the first studies assessing in vivo effects of PGE2 and the effects they demonstrated were 
indeed convincing, yet surprising. It should be noted, however, that the PGE2-treatment was 
performed in highly stimulatory conditions and in the presence of polarizing cytokines that may 
have affected the effects of the treatment, and which could partly explain the discrepancy with 
the previous observations. 
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1.6 HIV-1 infection and acquired immunodeficiency syndrome (AIDS) 
The human immunodeficiency virus (HIV) was first identified in 1983 as the cause of an 
outbreak of malignant disease in previously healthy, young, homosexual men in North America 
(29). More than 25 years of intense research has provided extensive knowledge on the virus and 
the immune pathologies associated with infection, along with a number of drugs efficient in 
keeping the virus at bay, though the prospects of a cure remain distant. Following years with 
steady progress and the development of several drugs with potent anti-viral properties, the field 
was practically swept off its feet by the disappointing outcome of the 2008 STEP trial, which 
was testing the efficaciousness and safety of what was intended to be the first HIV vaccine (63; 
256). The Merck HIV vaccine included in the trial consisted of a recombinant replication-
incompetent adenovirus type 5 (Ad5) expressing the HIV Gag, Pol, and Nef genes from subtype 
B strains of HIV. The vaccine was designed to induce T-cell immunity, and was hoped to 
prevent infection or reduce early viral burden in HIV-exposed individuals. Sadly – and 
surprisingly – it failed in both instances, and the trial was stopped following the first interim 
analysis. Thus, in spite of promising results in non-human primates (343; 351), the vaccine did 
not protect against infection, and did not reduce viral load in infected individuals. Instead, the 
data suggested an increase in the risk of HIV infection among the vaccinated male participants. 
In the wake of the disastrous results of the STEP trial, immunologists are now attempting 
other strategies for tempering and eliminating the HIV virus, turning to pristine viral targets in 
the development of new drugs and, furthermore, investigating the possibility of wielding 
endogenous immune mechanisms against the virus in newfound immunomodulatory therapies. 
1.6.1 The virus 
HIV is believed to have evolved from the simian immunodeficiency virus (SIV), which is 
known to infect primates, following transmission to humans sometime in the 19th or 20th 
century (301). Of the two viral strains that are pathogenic in humans HIV-1 is the strain 
responsible for the HIV pandemic that has now spread to every corner of the globe, whereas 
HIV-2 is confined to areas of West-Africa and considered less virulent (302). HIV (see Fig. 18 
for schematic structure) is transmitted through intimate sexual contact, through transmission of 
blood and blood products, and from mother to child during childbirth (180). The several cross-
species transmissions that must have occurred to generate the different subtypes of HIV-2 and 
the three HIV-1 groups are believed to result from the killing and handling of infected animals 
(154; 302). In humans, clade C is becoming the most prevalent of the HIV-1 clades, possibly as 
a result of the typically high viral set point in clade C infections and the abundance of virus 
found in genital fluids of infected patients (186). Of note, the clade C virus contains one or two 
47 
extra NF-κB sites compared to the other clades, which makes it more responsive to positive 
cytokine stimuli (182). Another factor contributing to the great variability of HIV is the rapid 
mutation rate, which implies that viruses with different genetic and biological properties may be 
found within the same individual as a result of independent evolution of viruses in distinct 
bodily compartments (128; 193; 434). Furthermore, co-infection with several viral strains in the 
same patient is not uncommon, and may lead to the emergence of recombinant viruses that are 
immunoevasive and resistant to certain drugs (75; 129; 360). 
HIV primarily infects immune cells (T cells and macrophages) that express the surface 
marker CD4. In addition, several other surface-bound molecules have been found to facilitate 
infection, including dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN; on 
dendritic cells), the LFAs, and the ICAMs (55; 167). However, viral tropism is mainly 
determined by the chemokine receptor(s), CCR5 and/or CXCR4, being used by the virus as co-
receptor for viral entry. Viruses targeting CCR5 (M-tropic) typically infect macrophages, 
whereas CXCR4-binding viruses (T-tropic) target established T-cell lines and generally appear 
only later in the infection (39). The virus tethers firmly to the target cell through binding to 
CD4 and co-receptors (see Fig. 19, page 50), and eventually injects its content into the cell by 
fusing with the plasma membrane (450). As the virus enters the cell the capsule is lost, resulting 
in the release of the reverse transcription complex into the cytosol. Components of this complex 
(in particular reverse transcriptase, RT) serve to convert the single-stranded viral RNA into 
double-stranded DNA. Subsequently, the newly synthesized DNA is translocated into the 
nucleus where the associated viral integrase and cellular repair enzymes serve to permanently 
integrate the viral DNA into the host genome (124). 
Figure 18: The human immuno-deficiency virus (HIV) consists of a capsular core, which contains the RNA
genome and the machinery required for host-genome integration; a protein coat; and a lipid membrane containing
envelope-protein spikes. Adapted from Collier and Oxford, 2006 (90). 
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As long as the infected cell remains quiescent, the integrated provirion will linger non-
symptomatically in the cell’s genome. However, the transcriptional activity of the cell increases 
upon activation, as does the availability of transcription factors and co-activator molecules 
(such as NF-κB) required for transcription of the viral DNA, leading to the generation of 
multiple copies of viral genomic RNA and the production of viral proteins. When all the 
required components of the virus are present, new virions reassemble in the cytoplasm and, 
eventually, bud off through the plasma membrane to create functional viruses. (124; 227) 
1.6.2 Why chronic? 
What primarily distinguishes HIV infection from most other infections is the fact that, in 
the vast majority of cases, the immune system is unable to clear the infection. The virus persists 
in the infected individual in spite of ongoing immune responses, and is capable of escaping the 
immune system by integrating as a provirion into the genome of infected cells. Importantly, 
many different somatic cell types, and not solely immune cells, may be infected by HIV and 
can serve as reservoirs for the virus during chronic infection (227). Once a virus has 
successfully integrated into the host genome it remains in the body as a latent infection and, 
even though the body is able to mount an effective immune response and all the circulating 
virus particles are eliminated, may reinvigorate the infection at a later time point. Another 
crucial point in HIV infection is that the virus predominantly infects immune cells. Unless the 
virus is transmitted directly through blood, the original infective unit is an M-tropic virus 
infecting CCR5-expressing macrophages that are present in mucosal tissues, most commonly at 
urogenital or rectal sites. However, HIV mutates frequently and already during the acute 
infection will T- tropic viruses emerge that are able to infect CXCR4-expressing activated T 
cells. Moreover, even though the virus may initially attain the latent state – during which it 
remains integrated in the genome of the infected cell – as soon as the T cell is activated, it will 
start producing multiple copies of the virion, as well as inflammatory mediators that facilitate 
its differentiation and proliferation. Soon, the newly synthesized HIV virions will escape the T 
cell by budding through the cell membrane, and the T cell will eventually succumb to the lytic 
pressure and undergo apoptosis (227). Thus, even though the immune system initially is 
capable of keeping the virus in check, the depletion of virus-specific T cells severely weakens 
anti-viral immunity over time. 
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Figure 19: Key aspects of the HIV life cycle. Although the human immunodeficiency virus (HIV) is able to
infect a variety of cell types, acquired immunodeficiency syndrome (AIDS) results from the depletion of CD4+ T-
helper lymphocyte cells, a key component of the human immune system. HIV enters the cell by docking to CD4
and using a chemokine receptor (either CCR5 or CXCR4) and other surface proteins to adhere firmly to the cell
and induce fusion with the plasma membrane. The viral capsid is released inside the cell, and the viral genome
integrates into the host genome by the actions of viral integrases. As viral genes are transcribed in activated CD4+
T cells, new viruses are formed that eventually lyse the cell as they bud off and are released into the surrounding
tissues. Adapted from Rambaut et al., 2004 (313). 
1.6.3 AIDS – an exhausting affair 
Weakened HIV-specific immunity alone does not explain the progression to AIDS 
(acquired immunodeficiency syndrome), which is characterized by a broadly acting immune 
deficiency that equally affects both HIV-specific immune responses and responses to other 
pathogens and malignancies. Several mechanisms are believed to contribute to the overall 
weakening of the immune system, one of which includes exhaustion of immune cells as a result 
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of chronic activation. The observed exhaustion has been associated with loss of proliferative 
capacity and limited functionality of a given immune cell, which relates to the expression of a 
set of inhibitory co-receptors, notably PD-1 and CTLA-4 (101; 398). In Paper 3, the 
simultaneous expression of PD-1 and CD38 was used to assess chronic activation. Furthermore, 
cellular exhaustion has been shown to correlate with prognostic markers such as viral load and 
CD4+ T-cell count in HIV patients (101; 172; 398). The observation that loss of PD-1 and 
CTLA-4 leads to autoimmunity in the respective knockout mice indicates that these molecules 
play important roles in the maintenance of immune homeostasis (82; 147). Normally, the 
balance between positive and negative regulation determines the outcome of TCR stimulation 
and weighs the T-cell response between activation and anergy. This may still be the case in 
chronic infection, but the balance has been severely skewed towards anergy by the abnormal 
hyperactivity of negative regulatory mechanisms. In the event of TCR stimulation, the 
expression of PD-1 and CTLA-4 on the cell surface is induced – in a manner dependent on 
nuclear factor of activated T cells (NFAT)-c1 – as part of a negative feedback mechanism 
(292). However, in face of chronic activation, the expression of these receptors are induced to 
such levels that the ability of the T cell to initiate a response becomes severely crippled. 
Moreover, should the T cell become activated, its functionality in terms of production of 
effector molecules is gravely limited. Thus, rather than generating polyfunctional responses, in 
which the T cell produces several cytokines and inflammatory factors, the response may be 
restricted to producing only one or two cytokines (13). 
The interaction of T-cell expressed PD-1 and CTLA-4 with their cognate receptors, B7-
H1 (PD-L1, where PD-L is PD ligand) or B7-DC (PD-L2) for PD-1 and B7-1 (CD80) or B7-2 
(CD86) for CTLA-4, negatively influences TCR signaling but may also convey ‘reverse 
signals’ through the B7 molecules and provide potentially important feedback to the APC. 
However, PD-L1, CD80, and CD86 may also be expressed on T cells and it has recently been 
shown that the interaction between PD-L1 and CD80 may confer inhibition of T-cell activation 
(67). CTLA-4 is also constitutively expressed on regulatory T cells and assumed to play a role 
in Treg-cell mediated suppression (125; 433). PD-1 is highly expressed on both CD4+ and 
CD8+ HIV-specific T cells (101; 304; 398). Interestingly, the expression of PD-1 on T cells 
specific for epitopes that had undergone a mutational escape was lower than on T cells 
recognizing conserved epitopes (375). The reduction in PD-1 expression following mutational 
escape was accompanied by regained polyfunctionality in these T cells, indicating that the 
exhaustion inflicted by high-level expression of PD-1 is reversible. Moreover, the findings in 
this longitudinal study suggested a link between modulation of PD-1 expression and the 
repeated exposure to cognate antigen (375). PD-1 levels may also be modulated in response to 
51 
TCR-independent stimuli, such as cytokine stimulation (199) or exposure to the accessory HIV 
protein Nef (273). Studies of CTLA-4 in HIV infection demonstrated a moderate 
overexpression of CTLA-4 in HIV-specific CTLs, which conferred suppression of HIV-specific 
CD4+ T-cell proliferation independent of the CTLA-4 expressed on Treg (188). In murine 
models of chronic infection, blockade of the PD-1 pathway has had promising effects in 
improving the response to therapeutic vaccination (153). Moreover, systemic administration of 
blocking antibodies to CTLA-4 was able to induce tumor regression in patients with metastatic 
melanoma or ovarian cancer, although at the cost of systemic inflammation (168; 305). One 
concern with therapeutic strategies directed against these inhibitory mechanisms, therefore, is 
the possibility of immune hyperactivity and autoimmunity. 
Other immunoregulatory mechanisms that have been implicated in HIV-1-associated 
immune suppression include IL-10 and cAMP, both of which have been addressed in the work 
presented in this Thesis (see Paper 1 and Paper 3, respectively). Interleukin-10 is a 
predominantly immunosuppressive cytokine known to suppress a wide variety of cells, 
including most, if not all, of the hematopoietic lineages, as well as a number of somatic cell 
types (264). This cytokine is known to potently inhibit the cytokine- and chemokine production 
of responder cells, as well as the expression of other inflammatory molecules and receptors, 
resulting in wide-spread immune suppression and the induction of anergic T cells. Notably, IL-
10 has been shown to be crucial to the induction and regulatory function of inducible regulatory 
T cells in mice. Furthermore, IL-10 has been involved in a number of immune pathologies, of 
which various cancers and persistent infections may be the most prominent (264). Moreover, 
IL-10 was linked to the pathogenesis of HIV, since the potencies of anti-HIV immune 
responses were inversely related to the concurrent levels of IL-10, and poor HIV-specific T-cell 
responses were restored by the addition of anti-IL-10 antibodies (88; 89; 218). Interestingly, IL-
10 has also been shown to inhibit the production of PGE2 through down-regulation of Cox-2, 
which was, in turn, shown to down-regulate the expression of matrix metalloproteinases in a 
mechanism dependent on cAMP (259; 279; 280). Moreover, the elevated levels of cAMP in T 
cells of HIV-infected patients was, in another study, shown to result in suppression of T-cell-
dependent immune responses through the activation of PKA type I (1). Notably, several other 
mechanisms of HIV-associated immune suppression have also been suggested, though the 
relative importance of the different mechanisms remains to be established. 
1.6.4 Tale of a survivor 
In February 2009 a team of medical doctors and scientists at Charité Universitätsmedizin 
Berlin published their sensational report on the first case ever to have been cured from HIV-1 
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infection (176). A 40-year old male HIV-1-infected patient underwent chemotherapy and stem-
cell therapy for acute myeloid leukemia. Following myeloablation and T-cell ablation of the 
patient, CD34+ peripheral-blood stem cells were transferred from a human leukocyte antigen 
(HLA)-identical donor that had previously been screened and found homozygous for the CCR5 
delta32 allele. Following two consecutive transplantations, complete remission of the acute 
myeloid leukemia was achieved. Twenty months after the first transplantation (and six months 
after the second), the patient remained healthy from his leukemia and free of plasma HIV-1 
RNA, even in the absence of HAART. (176) 
One important prerequisite for the success of this HIV-1-ablative strategy was the 
identification of an allogeneic stem-cell donor with identical HLA genotypes. Furthermore, the 
fact that the viral strains of the recipient were predominantly (97.1 %) CCR5-tropic, combined 
with the inability of the virus to infect residual long-lived CCR5-expressing macrophages, 
crucially contributed to the success of the endeavor (176). Overall, this report underscores the 
importance of the CCR5 co-receptor during HIV-1 infection and disease progression, and 
advocates further investigation into therapies targeting CCR5-mediated viral entry. Perhaps still 
more important, however, is the hope communicated by this sensational report to infected 
people and health-care professionals world-wide, nurturing the belief that HIV may, in fact, be 
cured. 
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2. Aims of the study 
The human immune system is extensively regulated and the modulation of 
immunoregulatory mechanisms represents a promising avenue for future immunotherapeutics. 
Regulatory T cells constitute one such mechanism that may be capable of controlling both 
autoimmunity and responses against infectious agents or malignancies. In addition, a number of 
molecular controls serve to direct and fine-tune immune responses on the subcellular level. 
These include the second messenger cAMP, which is known to control T-cell activation by 
inhibiting proximal TCR signaling in a cAMP–PKA–Csk inhibitory pathway. Cyclic AMP, in 
turn, is generated by adenylyl cyclases in response to a variety of different stimuli, of which 
some, like the prostaglandin PGE2, are produced by the inducible Cox-2 enzyme. 
The work presented in this Thesis has explored mechanisms of immune regulation at both 
cellular and sub-cellular levels, with the overall objective of elucidating the regulatory 
processes involved in HIV-associated immune dysfunction. Specifically, our aims were to: 
1. Investigate the suppressive properties and phenotype of HIV-1 antigen-specific T 
cells secreting IL-10 in chronic HIV. 
2. Design RI-specific PKA anchoring disruptor peptides of sufficient serum stability 
to be used in studies investigating the immunoregulatory role of PKA in vivo and, 
possibly, with the ability of alleviating immune dysfunction. 
3. Improve our basic understanding of the interaction between the regulatory subunit 
of PKA and its corresponding AKAP. 
4. Evaluate the potential of using the selective Cox-2 inhibitor celecoxib as 
immunomodulatory treatment in chronically HIV-infected, treatment-naive 
individuals. 
5. Examine the effect of treatment with Cox-2 inhibitors on the activation status and 
responsiveness of peripheral T cells. 
6. Investigate the possible influence of Cox-2 on the function of regulatory T cells. 
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3. Summary of Results 
Paper 1: Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-
specific T-cell population. 
In this paper, we investigated the possibility that a subset of HIV-1-specific T cells found 
in the peripheral blood of viremic HIV-positive individuals could harbor immunoregulatory 
properties, possibly contributing to the state of immune deficiency seen in individuals with 
progressive HIV-1 infection and AIDS. An immunosuppressive subset of HIV-1-specific T 
cells was indeed identified based on the capacity of this subset to produce and secrete the 
immunoregulatory cytokine IL-10. We isolated live, cytokine-secreting cells through the 
capture of IL-10 (or IFN-γ, in the control cells) on the surface of the respective cells using 
specific antibodies and targeting surface-bound IL-10 with immunomagnetic beads. The IL-10-
secreting cells were ultimately enriched on magnetic columns. They were subsequently 
phenotyped by FACS, and their ability to suppress the proliferation of normal T cells was 
determined in co-cultures using the CFSE dilution assay. We demonstrated that the suppressive 
capacity of the HIV-1-specific IL-10-secreting T cells was independent of FOXP3-expression, 
by which they resemble Tr1 cells. The number of these cells in peripheral blood turned out to 
be very low, which eventually hampered our attempts at determining their mechanism of action. 
Paper 2: Design of proteolytically stable RI anchoring disruptor peptidomimetics for in 
vivo studies of anchored type I protein kinase A-mediated signaling. 
This paper concerns the development of proteolytically stable peptidomimetics for 
disrupting the intracellular targeting of type I PKA. Starting with the sequence of the RIAD 
peptide recently published by our group (72), we introduced unnatural amino acids in strategic 
positions to increase the stability of the peptide. First, residues of the RIAD peptide that were 
particularly susceptible to proteolytic cleavage were identified in stability studies monitored by 
HPLC and mass spectrometry. Enzymatically protected RIAD analogs were designed by 
substituting labile residues with unnatural amino acids and, importantly, capping of the amino 
(N-) terminal leucine residue. The resulting peptidomimetics were tested with respect to 
specificity and affinity for PKA type I by membrane overlay with radio-labeled RI or RII. The 
stability of the analogs was determined by HPLC peak analysis following incubation in diluted 
human serum for varying amounts of time. The identity of the analogs and resulting metabolites 
was validated by mass-spectrometry. Finally, the newly designed peptidomimetics were tested 
in vitro regarding their capacity to reverse cAMP-mediated suppression of T-cell activation (in 
terms of IL-2-production; as assessed by enzyme-linked immunosorbent assay [ELISA] of 
culture supernatants). 
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PKA type I is known to regulate T-cell activation, and dysfunction in the cAMP–PKA–
Csk regulatory pathway has been implicated in the state of immune deficiency seen in 
progressive HIV-1-infection and AIDS. In this paper, RIAD analogs of improved enzymatic 
stability were designed that will aid in studying the involvement of PKA in immune function in 
vivo. We report a 50-fold improvement of the stability of these peptides compared to RIAD 
when tested in 30 % human serum in vitro. 
Paper 3: Cyclooxygenase type 2 inhibitor downregulates chronic immune activation, 
CD38, and PD-1 in patients with untreated HIV-1 infection. 
The third study included in this Thesis aimed to address the effects of treating healthy, 
treatment-naive, HIV-infected individuals with the selective Cox-2-inhibitor celecoxib. The 
study was performed as a prospective, open, exploratory trial and included 31 HIV-infected 
patients in total. The primary endpoints were the expression of CD38 and PD-1 on various T-
cell subsets as an indicator of immune activation and clinical progression. Effects of the 
celecoxib treatment were evident on CD38 and PD-1 levels, as well as on Treg numbers and 
function (as determined by CD25 depletion). Furthermore, the treatment induced changes in the 
susceptibility of T cells to indomethacin-mediated immune activation, possibly due to an up-
regulation of Cox-2 in T cells. Given the reduction in markers of chronic immune activation 
and T-cell exhaustion, in addition to an up-regulation of cytokine-secreting effector T cells, the 
treatment can be said to have had a positive effect on immune function. It would be reasonable 
to expect that at least some of these effects were the result of reduced intracellular levels of 
cAMP. Thus, it is conceivable that celecoxib and other Cox-2 inhibitors may be useful immune 
modulating additions to the treatment of HIV. 
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4. Discussion 
In the introduction of this Thesis, the central principles of immunity and immune 
regulation were laid down, to provide an understanding of the tightly regulated processes of an 
immune response. From this information we may, perhaps, begin to grasp the complexity of the 
systems we rely on for our good health and admire the fact that, most of the time, the numerous 
intricate systems that constitute our immune system manage to keep us healthy and strong. 
However, faulty immune responses do occur and, in cases such as autoimmune diseases and 
cancer, have been known to cause disease. The present Thesis has focused on the regulatory 
mechanisms that are put in place to avoid aberrant immune activation and limit immune 
pathology, addressing the potential of manipulating these mechanisms in a therapeutic context. 
Emphasis has been put on the emerging idea that exaggerated immune regulation may 
contribute to immune deficiencies, as seen in HIV infection, or suppress immunity against 
malignant cells. As far as the treatment of autoimmune diseases is concerned, this has 
traditionally relied on “shotgun therapies”, i.e. drug regimens that tend to knock out the entire 
immune system, or at least large parts of it, in order to keep the pathogenic processes at bay. 
This type of treatment comes with severe side effects and a high risk of attracting serious 
infections (see Table 1). On the other hand, treatments directed at improving immune responses 
in sub-immunogenic individuals are few and with limited applicability (Table 2). These, as 
well, suffer from side effects and are frequently inefficient at restoring immunity. Hence, by 
identifying new and more specific targets for immune modulation, we hope to improve the 
treatment of immune-mediated diseases. 
Table 1: The immunosuppressive drugs currently marketed in Norway. The table lists the immunosuppressive
drugs that are currently on the market, indicating their mechanism of action and including a list of their most
common adverse effects. The most important therapeutic uses are noted, as well. IBD, inflammatory bowel
disease; ALL, acute lymphocytic leukemia; MS, multiple sclerosis; RA, rheumatoid arthritis; CLL, chronic
lymphocytic leukemia; PA, psoriatic arthritis; GVHD, graft-versus-host disease; SLE, systemic lupus
erythematosus; WG, Wegener’s granulomatosis. Sources: Felleskatalogen, 2009 (97); Legemiddelhåndboken,
2007 (126). 
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Table 2: The immunostimulatory agents currently
marketed in Norway. The table lists the
immunostimulatory drugs that are currently on the
market, indicating their mechanism of action and
including a list of their most common adverse
effects. The most important therapeutic uses are
noted, as well. Sources: Felleskatalogen, 2009 (97);
Legemiddelhåndboken, 2007 (126). 
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4.1 A global view of immune regulation 
‘Immune regulation’ as a phenomenon spans a wide range of mechanisms, ranging from 
regulation of homeostatic output of immune cells in the bone marrow to modulation of the 
signaling of peripheral effector cells. As suggested above, the modalities currently available for 
treating immune-mediated diseases suffer a number of shortcomings, of which a lack of 
efficacy and frequent serious adverse events are among the major concerns. Improved therapies 
are expected to spring from the identification of molecular mechanisms that may be specifically 
targeted. In this respect, efficacy is maintained only to the extent that the targeted entity 
effectively controls the pathogenic mechanism. Moreover, specificity – and, thereby, the 
desired reduction in adverse effects – requires limited influence of the targeted mechanism over 
other immunological and physiological processes. 
In the present Thesis, modulation of T-cell activation through the inhibition of PKA type I 
has been presented as a putative treatment strategy for various immune deficiencies, including 
AIDS (Paper 2). Indeed, the peptidomimetics that we have developed selectively target PKA 
type I over type II PKA, and are able to disrupt the functions of PKA type I without affecting 
processes dependent on PKA type II (Paper 2). However, this does not address the fact that 
PKA type I is also expressed in other cell types than T cells, and that administration of the 
peptidomimetics in vivo may cause side effects that are unrelated to the immunoregulatory 
mechanism we wish to target. Yet it remains conceivable that intravenous administration, 
combined with low dosage, allows for selective treatment of circulating blood cells and 
sufficiently discriminates between these and tissue cells to avoid adverse effects. It is also 
possible that any effect imposed on other cell types by transient inhibition of PKA type I is 
clinically irrelevant. Thus, in planning for improved immunomodulatory therapies, not only is 
the specificity of the chosen target mechanism crucial; the drug itself will also have to be highly 
specific in its actions. 
From what was outlined in the introductory chapters of this Thesis, we may gather that 
regulation is the rule rather than the exception in the realm of immunity. Figure 20 summarizes 
the most important checkpoints for a given immune response. Importantly, all of these 
checkpoints represent putative targets for immunotherapy. For example, it could be of interest 
to administer an agent that would shift the thymic T-cell output towards more nTreg in 
individuals suffering from autoimmune diseases. Of note, induction of iTreg in the periphery 
could serve the same purpose, and even be more efficient if antigen specificity was required for 
optimal suppression. Such non-invasive modulation of Treg remains largely untested, although 
some reports have claimed Treg-modulating effects of some registered drugs (see Section 4.3). 
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On the other hand, the adoptive transfer of ex vivo isolated and/or expanded Treg could 
represent a more imminent feat (see Section 4.2). The homing of immune cells to specific 
tissues may be utilized in immunotherapy, as may the requirement for inflammatory factors and 
co-stimulation for activation of these cells when appropriately positioned in the respective 
tissues. Moreover, the antigen presentation itself could constitute another interceptive focus. As 
we have seen, the DC may, for instance, attain either an inflammatory or a tolerizing state, 
which directly affects the response of peptide–MHC-cognate lymphocytes by inducing either 
activation or tolerance. Furthermore, the intracellular signaling that ensues in the T cell 
following interaction with an APC may pose another range of possible targets, as even subtle 
changes in the different signaling pathways have been seen to abruptly modify the functions of 
a lymphocyte. The question is: At which level do we achieve the highest specificity? Or, in 
terms of developing drugs that can be used to treat a range of pathologies, which level should 
be targeted to achieve the greatest versatility? 
Figure 20: Regulation abounds. Every critical step of the immune response is subject to regulation. Key check
points include lymphopoiesis and clonal selection in the primary lymphoid tissues; activation and maturation in
secondary lymphoid tissues; and generation of effector responses in the periphery. Both extrinsic and intrinsic
mechanisms are put in place to ensure timely responses against potential threats based on the relative abundance of
incoming stimulatory and inhibitory signals, respectively. These may result from cell contact or the release of
soluble signaling molecules.
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Regardless of what level is chosen, it will always remain important to maintain a global 
view of the perturbations we introduce to modulate immunity: Although we see the desired 
effects in T cells, adverse effects may occur elsewhere. Hence, if the aim is to administer an 
immunomodulatory drug systemically, we will have to consider what other systems will be 
affected and, if necessary, provide means to ensure targeted delivery of the drug or otherwise 
limit its adverse effects. 
4.2 Harnessing the regulatory properties of Treg for therapeutic purposes 
The leading principle of modern medicine says that any pharmacological intervention 
should aim to maintain a healthy balance between the expected benefit of the treatment, versus 
the potential risk. However, it does preclude a significant number of patients with immune-
mediated diseases from getting the most effective treatment, due to a high risk of side effects. 
Thus, providing new, targeted therapies with a smaller risk of side effects could result in 
improved quality of life for a great number of patients. Therefore, the identification of targets 
with potential value for the treatment of immune-mediated diseases has been a major focal 
point over the recent years of medical research. In this respect, the identification of regulatory T 
cells has been particularly intriguing. 
Since the discovery of regulatory T cells, the possibility of utilizing these cells in immune 
therapy has attracted substantial interest. Their therapeutic potential was recognized as early as 
in 1975 (137), yet decades later we are still awaiting the results from the first clinical studies 
(319). However, evidence of the potential effects of such a therapy has, since then, been 
demonstrated in a series of studies looking at the effects of removing and adoptively 
transferring specific T-cell subsets in mice (258; 311; 328; 362; 376), and the first report 
identifying the suppressive subset as CD4+CD25+ T cells was published in 1995 (330). 
Importantly, in these studies, tolerance could be restored by the adoptive transfer of the T-cell 
populations that had originally been removed, further substantiating the possible link to a new 
form of cell-mediated immunotherapy. One important lesson learnt from these studies was that 
loss of regulatory T cells (Treg) by itself can be sufficient to induce autoimmunity. This notion 
has been compellingly corroborated by the finding that loss-of-function mutations in the 
FOXP3 gene, encoding the Treg ‘master-switch’ transcription factor FOXP3, results in a 
syndrome characterized by multiple autoimmune diseases in humans, known as the IPEX 
syndrome (37; 430). Correspondingly, mutations in the murine ortholog of FOXP3, scurfy, 
were found to be responsible for the lethal scurfy phenotype in mice (62). 
Several potential issues have held back the process of translating adoptive Treg therapy 
from the pre-clinical studies to clinical practice. First of all, there is the issue of safety, which 
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puts stringent demands on the quality of clinical Treg isolates. According to the U.S. Food and 
Drug Administration (FDA) these have to be sterile, identifiable, pure, and with a proven 
potency (319). However, the preparation of Treg isolates is a complex process, especially when 
it comes to preparing large-scale isolates that are to be used in human beings: First, there is a 
limited availability of Treg in human donors, as Treg donated from adults will have to come 
from peripheral blood or from bone marrow. Alternatively, Treg may be isolated from frozen 
umbilical cords (141). Regardless, the large number of cells required for therapeutic purposes 
necessitates ex vivo expansion of the isolated Treg. This, however, is complicated by the fact 
that effector T cells (Teff) are more easily expanded than Treg, implying a risk of amplifying 
Teff impurities that were present in the original isolate. One recent advance that may facilitate 
selective expansion of Treg in vitro involves treating the cultures with the immunosuppressant 
rapamycin, which preferentially preserves Treg over Teff due to the FOXP3-induced expression 
of a kinase (Pim2) that confers rapamycin resistance (31; 33). 
Another major hurdle to the introduction of adoptive Treg therapy lies in demonstrating 
the potency of the product prior to administration to the patient, since standardized in vitro 
procedures for this task has yet to be defined. Quite significant to this end is the fact that, 
although multiple mechanisms have been suggested, we lack a clear understanding of how 
Treg-mediated suppression comes about in vivo (388). Moreover, the suppressive capacity 
observed in vitro does not necessarily correlate well with the ability to suppress in vivo (144). 
The recent development of humanized animal models carrying human immune systems may aid 
in the assessment of in vivo suppressive responses with human Treg (355; 417), though it 
remains to be seen whether they will be able to predict therapeutic value in humans. 
The adoptive transfer of Treg has been tested in a variety of autoimmune diseases in 
mice, of which the results from models of type-1 diabetes (T1D) and graft-versus-host disease 
(GVHD) related to hematopoietic stem cell transplantation (HSCT) have shown the greatest 
promise: Several studies have demonstrated the potential benefit of adoptively transferring 
either polyclonal or antigen-specific Treg into non-obese diabetic (NOD) mice, which are 
otherwise prone to acquiring T1D (385; 389; 390). Similarly, the adoptive transfer of freshly 
isolated or expanded Treg into recently grafted recipients prevented acute as well as chronic 
GVHD (392; 454). Furthermore, in vivo activated Treg have been shown capable of 
ameliorating ongoing chronic GVHD (15; 454). These successes collectively constitute a strong 
advocacy for the continued efforts in bringing adoptive immunotherapy into clinical practice, 
although several challenges remain. 
There is, presently, a considerable body of evidence indicating a contribution of Treg in 
infections (2; 36; 212), during tumor progression (32; 94), or following allogeneic 
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transplantations (399). Other examples of Treg-related autoimmunity exist, like type I diabetes 
(T1D), systemic lupus erythematosus (SLE), and Sjögren’s syndrome, yet the precise links of 
these disorders to Treg dysfunction are less clear. Thus, in all of these diseases there is a 
potential benefit of employing adoptive Treg therapy. In other autoimmune disorders, like 
multiple sclerosis (MS), parts of the available data point to increased resistance of the Teff to 
suppression rather than reduced function of the Treg per se, possibly resulting from an 
inflammatory environment (228). Related to this, it has been suggested that the high secretion 
by Teff of the cytokines IL-6 and TNF-α may have reinforced their inflammatory activities and 
protected them from inhibition (207). 
The HIV-1-specific IL-10-secreting Treg described in Paper 1 constitute a population of 
potent regulatory T cells that could have potential use in alleviating hyper-activation of HIV-1-
specific T effector cells. Notably, it has been suggested that chronic activation may result in 
exhaustion of the T cells, and that a measured reduction in the response could improve immune 
competence (64). Also, such a strategy might reduce the number of activated T cells expressing 
the HIV co-receptors (CCR5 or CXCR4), thereby limiting the availability of T cells susceptible 
to HIV infection and, thus, the propagation of the virus. 
4.3 Targeting Treg as a means of improving immune function 
Given the suppressive nature of Treg and their alleged involvement in the promotion of 
malignancies and chronic infection, there has been some interest in wielding this regulatory T-
cell subset in favor of human health by pharmacological means. The feasibility of this approach 
was indicated in studies reporting inhibitory effects of traditional drugs on the number and 
activities of Treg. These include several cancer drugs, such as cyclophosphamide (139), 
gemcitabine (382), and fludarabine (43), as well as the NSAID indomethacin (443) and the 
selective Cox-2 inhibitor celecoxib (Paper 3, indirectly). In recent years, a number of reagents 
have been developed that specifically target Treg, most of which take advantage of surface 
proteins that are preferentially Treg-expressed. One example is the depletion of Treg in vivo by 
administration of anti-CD25 antibodies, which has been achieved in mice but remains to be 
tested in humans. Other Treg-depleting agents include chimeric fusion proteins that consist of 
anti-CD25 in one end and a recombinant toxic protein in the other, one example being LMB-2, 
which combines the single-chain Fv fragment of anti-CD25 and a 38 kDa fragment of 
Pseudomonas exotoxin A. LMB-2 has shown Treg-depleting properties in a phase I study 
among patients with CD25+ T-cell malignancies (310). Another fusion protein called 
denileukin diftitox combines recombinant human IL-2 with the enzymatically active domain of 
diphteria toxin. Upon binding to the high-affinity IL-2 receptor (consisting of CD25, CD122, 
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and CD123) the toxin is internalized, leading to cell lysis. Diftitox has been tested in several 
phase I studies, of which some have indicated a benefit of depleting Treg in terms of improved 
tumor-specific immune responses (248; 315). Correspondingly, the depletion of Treg has been 
shown to improve vaccine-induced responses as well, and one emerging strategy for improving 
immune responses in cancer therapy constitutes the combined use of Treg-depletion and 
vaccination or other immunomodulatory therapy (98; 239; 267; 324). Some controversy 
persists, though, with respect to the robustness of the Treg depletion, and regarding the clinical 
value of the procedure (23; 283). Rapid reversal of the Treg levels after depletion has been 
observed in some studies, suggesting that repeated therapy may be required. Notably, however, 
up to 75 % of the Treg generated after the first treatment were treatment refractory (98; 309). 
CTLA-4 is another putative target for therapies modulating Treg activity and function. It 
is constitutively expressed on Treg and has been suggested to mediate Treg suppression through 
binding to the CD28 ligands CD80 and CD86 expressed on APCs (317; 335). Thus, CTLA-4 
prevents the interaction of CD80 and CD86 with T-cell expressed CD28, which is a prerequisite 
for potent T-cell activation. The important role of CTLA-4 in immune homeostasis has been 
demonstrated using CTLA-4-deficient mice, which suffer death at an early age following 
massive lymphoproliferation and multi-organ failure (394; 425). The use of anti-CTLA-4 
therapy has been evaluated in humans, and two humanized anti-CTLA-4 blocking antibodies 
(ipilimumab and tremelimumab) have been tested in phase I/II trials (68; 336). Ipilimumab – 
which is the more extensively studied of these two – has demonstrated efficacy in several phase 
II trials, involving more than 300 patients with advanced melanoma (336). Between 10 and 15 
per cent of the patients experienced complete or partial therapeutic responses. Furthermore, the 
study participants had a median survival of around 15 months, as opposed to a median range of 
6 to 9 months without treatment. Unfortunately, there appeared to be a correlation between 
clinical efficaciousness and severe immune-related adverse events, which affected up to 40 % 
of the patients. However, although the immune-related adverse events may have been serious, 
they were manageable and generally reversible if treated promptly (336). 
The hope is that, with the use of these new agents, pathogen-specific immunity and anti-
tumor immune responses may be improved by the specific depletion or modulation of Treg. 
4.4 PKA as a putative target for immunotherapy 
Cyclic AMP serves a variety of functions and is expressed in every cell of the human 
body. In T cells, this second messenger is known to inhibit growth, differentiation, and 
proliferation (47). Precisely how these suppressive effects are exerted remains largely 
unknown, however. Treg express high levels of cAMP even in the resting state, whereas in 
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CD4+ effector T cells only negligible levels are found (50). This may be explained by the 
strongly reduced levels of the cAMP phosphodiesterase PDE3B in Treg (50; 133), which would 
otherwise keep the cAMP-levels in check. Thus, high levels of endogenous cAMP may be 
responsible for the anergic phenotype of Treg, as well as central to their suppressive actions. 
Interestingly, pharmacological interventions that seek to normalize the elevated cAMP levels or 
block cAMP function have been shown to prevent nTreg-mediated suppression. Examples 
include co-stimulation through CD28 – which recruit PDE4 (4) – and the selective antagonism 
of cAMP and its receptors (364). 
The most prominent cAMP receptor in T cells, the cAMP-dependent kinase PKA, has 
been suggested by several studies to harbor immunoregulatory properties (341; 396). Moreover, 
if nothing else, the death at the embryonic stage of RIα -/- knockout mice suggests that PKA 
type I plays an important role in the developing embryo (14). Furthermore, the finding that RIIα 
-/- knockout mice survive and display normal immune function (340) effectively dismisses type 
II PKA from the current discussion of potential targets for immunotherapy, as this isozyme 
appears not to be necessary for a well-functioning immune system. The involvement in immune 
regulation of PKA type I, on the other hand, has been corroborated by a number of studies: 
Using isoform-specific cAMP analogs, Skålhegg and colleagues were the first to identify PKA 
type I as the cAMP receptor regulating T-cell activation upon ligation of the TCR (358). In a 
follow-up study, they went on to demonstrate that PKA type I translocates and interacts with 
the TCR-CD3 complex (359). More recently, it was shown that PKA type I inhibits T-cell 
signaling through the activation of Csk, thereby inactivating the tyrosine kinase Lck and 
preventing the phosphorylation of CD3 ζ-chains, resulting in blockade of the TCR-proximal 
events that would normally lead to T-cell activation (409). Since then, several other studies 
have substantiated the initial findings, also demonstrating the involvement of the cAMP-
degrading PDEs and the importance of PKA type I anchoring and targeting to lipid rafts for 
cAMP-mediated regulation of T-cell responses (3; 4; 244; 314; 322; 408; 462). Thus, 
substantial data advocates the pharmacological targeting of PKA type I for immunoregulatory 
purposes. In this context, the design of stable anchoring disruptor peptidomimetics for the 
displacement of PKA from lipid rafts (Paper 2) or isoform-specific cAMP analogs that block 
the activation of PKA type I may prove important steps in developing treatment modalities that 
specifically target the PKA type I-mediated inhibition of T-cell activation. 
Very recently, a report by Becker and colleagues (35) suggested that upregulation of 
cAMP was responsible for mediating tolerance in response to ligation of HIV-1 gp120 to cell-
surface expressed CD4 on CD4+CD25+ nTreg. They found that gp120-mediated activation of 
CD4 on Treg, but not Teff, resulted in activation of ACs and production of cAMP (35). 
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However, whether or not PKA type I was involved in this mechanism was not specifically 
assessed. Previously, Bopp and colleagues have identified intercellular transfer of cAMP 
through gap-junctions as a mechanism for Treg-mediated suppression (50; 51), which may also 
account for the tolerizing effects of gp120. Correspondingly, an upregulation of intracellular 
CTLA-4-levels upon ligation of gp120 may signify Treg activation (35). Thus, the selective 
activation of Treg with gp120 could constitute a new way of inducing immunological tolerance 
in vivo. Consequently, recombinant gp120 may represent a promising agent for in vivo 
immunomodulatory therapy, activating Treg in a cAMP-dependent manner. This observation 
further underlines the importance of cAMP as immune regulator. 
4.5 Immunomodulatory roles of IL-10 and IL-10-producing Treg 
Numerous studies in mice have demonstrated the important role of IL-10 in curtailing 
autoimmunity and its potentially detrimental effect of suppressing desirable immune responses. 
This duality of IL-10 indicates the need for tight regulation of its expression, but also points to 
its potential uses in immunotherapy (269). IL-10-deficient mice have been shown to succumb to 
what are normally sublethal doses of lipopolysaccharide (LPS) (38), and to develop lethal 
autoimmunity while failing to eliminate what would normally be self-contained bacterial and 
parasitic infections (136; 175). Moreover, mice lacking IL-10 typically experience exacerbated 
disease when exposed to murine models of autoimmunity, such as EAE, IBD, and rheumatoid 
arthritis (RA) (269). In contrast, overexpression of IL-10 results in powerful immune 
suppression, which may allow for tumor growth and the occurrence of lethal infections (269). 
Recombinant IL-10 has been tested in several clinical trials over the last decade, in 
general being well tolerated yet inadequately controlling autoimmune symptoms – except for 
some trials, in which IL-10 was administered locally, for instance directly beneath psoriatic 
lesions of the skin (344). In Crohn’s disease, administration of IL-10 through ingestion of 
genetically modified IL-10-secreting bacteria seems to have some potential (58; 76; 371). 
Moreover, ingested gelatin nanoparticles containing copies of the IL-10 gene were shown to 
accumulate in the large intestine and provide local expression of IL-10 and relief of 
inflammatory symptoms in a murine model of acute colitis (44). Conversely, antibodies to IL-
10 or its receptor may be used to prevent or reverse IL-10-mediated immune suppression, or 
enhance immune responses against infection or upon vaccination. For example, blocking IL-10 
while administering a DNA vaccine against lymphocytic choriomeningitis virus (LCMV) 
improved vaccine responses and resulted in subsequent protection against infection (61). 
Furthermore, IL-10-receptor blockade in persistent LCMV infection resulted in a rapid 
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resolution of the infection (114). A similar effect was found in bacterial infections, exemplified 
by infections with Mycobacterium avian (321; 356). 
The overall effect of IL-10 is to shift an immune response towards a Th2-type humoral 
response, whereas treatment with anti-IL-10 will favor a Th1 response with cellular immunity 
(287). Also, the capacity of DCs to present tumor antigens is diminished by IL-10 (255). Thus, 
as many solid tumors secrete IL-10 themselves (264; 431), or induce the secretion of IL-10 by 
bystander cells or tumor-associated IL-10-producing Treg (94; 252), cellular immunity is 
impeded. Hence, therapeutic blockade of IL-10 through administration of monoclonal 
antibodies restores immune function and, when administered along with cytotoxic drugs and/or 
immunostimulatory agents (e.g., TLR ligands), may facilitate elimination of the tumor (269). 
The IL-10-secreting suppressive cells described in Paper 1 are, admittedly, unlikely to 
make it to the bedside, mainly because of their scarcity in peripheral blood. However, based on 
recent advances in the procedures developed for adoptive Treg therapy, it is conceivable that 
future progress might enable the generation of highly specific suppressor-cell clones from one 
cell alone. Methodologies might also evolve to allow for generation of Treg with increased 
suppressive capacity, thus reducing the number of cells required for an efficacious adoptive 
transfer. In this respect, Treg suppressing through soluble mediators or capable of inducing 
bystander suppression may prove more potent than Treg relying on contact-dependent 
suppressive mechanisms. The HIV-1-specific IL-10-secreting T cells identified in Paper 1 were 
indeed rather potent in their suppression of the proliferative responses of Teff in vitro. 
Unfortunately, their suppressive mechanism of action could not be elucidated in the present 
work, but should be pursued in future studies. It seems likely that their site of action in vivo 
would be secondary lymphoid tissues rather than peripheral blood, enabling them to interact 
more closely with their activated target cells, and probably improving their numbers relative to 
the number of target cells. An assessment of the homing receptors expressed on the surface of 
the cells could serve to indicate their site of action. In addition, analyzing the release of soluble 
inflammatory or anti-inflammatory mediators such as cytokines and chemokines could reveal 
some of their functional properties. The recent advent of multiplexing techniques has allowed 
the concurrent analysis of up to several hundreds of different factors from one sample. 
Moreover, the genome-wide chip (microarray) analyses constitute a powerful strategy for 
assessing the transcriptional processes within a cell, simultaneously detecting mRNA 
transcripts from every gene expressed. Finally, the epigenetic status of the cell, as judged by the 
presence of various non-coding modifications of the chromatin structure or the DNA itself, 
indicate the segments of the genome that are transcriptionally active and may provide additional 
info on the properties of a cell. With the recent advances in molecular biology one cell can 
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indeed be enough – given robust expression of the molecule in question – although improved 
precision of the analysis generally correlates with higher cell numbers. Other procedures that 
should be attempted include the blockade of putative or known secreted factors, as well as the 
cloning and expansion of single cells to see if their suppressive tendencies are heritable, and if 
they could be reversed in any way – for instance by the application of polarizing conditions 
favoring other T-cell lineages, such as Th1, Th2, or Th17. 
4.6 Current efforts in the development of new immunotherapies 
Academic and corporate scientists worldwide are currently racing to develop new 
candidate immunotherapeutics, and various strategies are employed in targeting ‘anything that 
moves’ among numerous promising targets. It would be well beyond the scope of this Thesis to 
present all of these efforts comprehensively, though the following chapters will deal with some 
of the candidates that aim to regulate immunity by modulating cytokine responses. This is a 
field that has seen substantial progress over the last couple of years, and the strategies used for 
targeting cytokines in immune cells may also be used in targeting other regulatory mechanisms. 
4.6.1 Putative new targets for small-molecular compounds 
Small-molecular synthetic compounds represent the mainstay of conventional drug 
therapy. However, a large portion of the currently marketed drugs are based on compounds that 
were discovered empirically, for which we still lack a plausible mechanism of action. The 
design of small-molecule mimetics constitutes a more refined approach, employing state-of-the-
art technologies to predict structures that will have a certain pharmacological action. The 
tyrosine-kinase inhibitor peptide (TKIP) is one example of a recently developed small-molecule 
mimetic that has been tested in vivo. TKIP is a SOCS-1 mimic designed to bind the 
autophosphorylation site of JAK-2, thereby inhibiting the phosphorylation and activation of 
STAT1α as well as STAT3. This peptide has been shown to inhibit both constitutive and IL-6-
induced STAT3 activation in several human prostate cancer cell lines, and may represent a 
promising therapeutic for STAT1/STAT3-dysregulated malignancies (120). In addition, the 
TKIP peptide was shown to protect against EAE in mice, indicating that it could also be 
developed into drugs targeting neurodegenerative autoimmune disorders such as multiple 
sclerosis (271). 
JAK-3 may be another target for a new line of immunotherapeutic drugs. It is expressed 
only in hematopoietic cells, and inducibly so in T cells, B cells, and myeloid cells, providing an 
interesting drug target for inflammatory diseases (245; 299). Loss-of-function mutations in the 
JAK-3 gene results in immunodeficiency, albeit without the pleiotropic effects seen with current 
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immunosuppressive treatments like cyclosporine A, tacrolimus, and steroids (291). Therefore, 
specific targeting of JAK-3 with a small-molecule inhibitor may alleviate autoimmune 
symptoms with a smaller degree of side effects than the traditional therapies. Notably, the CP-
690,550 compound from Pfizer has already been tested in a phase 1 trial following promising 
results in the pre-clinical studies, and was shown to be safe in humans (404). 
4.6.2 Treatment with recombinant proteins or expression systems 
Cytokines pose an interesting target for immunotherapeutics due to their importance in 
regulating immune responses, and to the fact that a number of inflammatory diseases are caused 
by aberrant cytokine signaling (447). An important regulator of cytokine signaling is the SOCS 
family of proteins, which bind to intracellular moieties of cytokine receptors to block the 
initiation of STAT signaling, as outlined in Section 1.3.2 of the introduction. Normally, SOCS 
proteins are induced upon cytokine signaling to provide negative feedback, and this may be 
exploited therapeutically by overexpressing specific SOCS proteins. Thus, in a recent study, the 
development of rheumatoid arthritis in murine models was prevented by the overexpression of 
SOCS3 (352). Furthermore, the administration of SOCS3 fusion proteins was shown to be 
effective in curtailing inflammation in mice challenged with superantigen and other pathogen-
derived inflammatory molecules (185). Conversely, the expression of dominant-negative SOCS 
proteins might be used to enhance cytokine signaling and improve anti-tumor or anti-viral 
immunity, though the feasibility of this approach has so far not been tested in vivo (447). 
The use of monoclonal antibodies to block the effects of inflammatory cytokines has 
already achieved clinical approval in a number of inflammatory diseases (54; 205; 243; 372; 
373). This strategy has proven effective in alleviating chronic inflammation in patients with 
Crohn’s disease (250) and psoriasis (211), as well as rheumatoid arthritis (115). Specifically 
blocking the inflammatory actions of cytokines using antibodies directed against the cytokines 
themselves or against subunits of their receptors thus constitutes a promising and well-tested 
mode of anti-inflammatory therapy. Recently, an antibody against the common p40 subunit of 
IL-12 and IL-23 receptors was developed that has the potential to broadly alleviate 
inflammation caused by the two inflammatory cytokines IL-12 and IL-23. A phase III study is 
currently underway to test the clinical efficacy of the ABT-874 antibody (also known as 
briakinumab), after successful phase I and phase II studies (198; 236). 
4.6.3 RNA silencing 
Several studies have used siRNA to reduce the levels of SOCS proteins in different 
systems, demonstrating a great diversity in the possible applications for such a therapeutic 
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strategy. One promising application would be in DC-based tumor vaccines, as treatment of DCs 
with Socs1 siRNA was shown to significantly improve the ability to break tolerance and induce 
anti-tumor immunity, primarily as a result of improved antigen presentation (116; 348). 
Furthermore, systemic administration of Socs1 siRNA using single-walled nanotubes as carriers 
to target phagocytic APCs could slow the growth of established tumors in a mouse model with 
peripherally injected B16 tumor cells (437). Interestingly, this approach could also be used to 
enhance the efficiency of DNA- or DC-based HIV vaccines in mice, as assessed by in vitro 
HIV-specific immune responses following vaccination (367). Moreover, antisense RNA 
therapy targeting Socs-1 and Socs-3 as a means of reducing SOCS expression and improve 
cytokine responsiveness in obese diabetic mice improved insulin sensitivity and ameliorated 
hepatic steatosis and hypertriglyceridemia, which are hall-marks of diabetic or pre-diabetic 
patients suffering metabolic syndrome (401). 
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5. Conclusions 
In the present Thesis, cellular as well as molecular regulatory mechanisms were evaluated 
in the interest of paving the way for new immunomodulatory therapies. 
1. A subset of IL-10-secreting HIV-1-specific T cells was identified that was capable 
of inhibiting T-cell proliferative responses in vitro. Based on these data, we find it 
likely that HIV-1-specific T cells contribute to the immune deficiency observed in 
progressive HIV infection and AIDS. Akin to Tr1 regulatory T cells, these cells 
did not express the canonical transcription factor FOXP3. 
2. RI-specific anchoring disruptor peptidomimetics of improved stability were 
successfully designed, and should be able to withstand the proteolytic enzymes of 
serum to an extent that allows their use in live animals. For the first time, the 
implications of anchored PKA type I in the regulation of T-cell responses may 
now be studied through pharmacological intervention in vivo. 
3. Through site-specific substitutions in the RIAD sequence we have extended our 
understanding of the interaction between the regulatory subunit dimer of PKA 
type I and its AKAP ligand, and identified residues that may be substituted 
without compromising the affinity or the specificity of the peptide for RI. 
4. We observed a possible immunoregulatory effect of the selective Cox-2 inhibitor 
celecoxib in chronically infected HIV-positive individuals: Patients treated with 
celecoxib for 12 weeks experienced a reduction in the levels of T-cell expressed 
CD38 and PD-1, which represent markers of immune hyperactivation and 
exhaustion that have prognostic value in HIV. 
5. Through the depletion of CD25-expressing PBMC we showed that a higher 
proportion of the CD25+ cells appeared to produce effector T-cell cytokines (IFN-
γ and TNF-α) after celecoxib treatment, indicating diminished influence of Treg 
upon treatment with celecoxib. This points to a possible effect of Cox-2 inhibitors 
on Treg. 
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